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ABBREVIATIONS 
AA – aminoacids  
ADPKD – Autosomal dominant polycystic kidney disease  
ARPKD – Autosomal recessive polycystic kidney disease  
DMEM – Dulbecco’s modiﬁed Eagle’s Medium 
eIF3 – eukaryotic initiation factor 3  
eIF4E – eukaryotic initiation factor 4E 
FAK – focal adhesions 
FBS – Fetal Bovine Serum  
GFR – Glomerular Filtration Rate  
GH – Growth hormone 
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HEK293 - Human Embryonic Kidney 293 cells 
IND - Ofd1fl/y;creER-TM mutants 
Ksp mutants – Ofd1fl;creKsp conditional mutants  
MDCK – Madin-Darby Canine Kidney Cells 
mTOR – mammalian target of rapamycin  
NPHP – nephronophthisis 
OFDI – Oral -Facial-Digital type I syndrome 
Pc 1 and 2 – polycystin1 and 2 
PIC – pre-initiation complex of translation 
PKD – Polycystic Kidney Disease 
RT – Room Temperature 
SEM – Scanning electron microscopy 
siRNA - small interfering RNA 
TSC – tuberous sclerosis  
WT – wild type 
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ABSTRACT 
The Oral-Facial-Digital type I syndrome (OFDI; MIM 311200) is a rare syndromic form of inherited renal cystic 
disease. It is transmitted as an X-linked dominant, male lethal disorder and is caused by mutations in the OFD1 
gene. Previous studies demonstrated that OFDI belongs to the growing number of disorders ascribed to 
dysfunction of primary cilia. Among the different clinical signs OFD type I is characterized by the presence of 
renal cystic disease, which is present in over 60% of cases. With the purpose of studying the role of the Ofd1 
transcript in renal cystic disease, we generated two conditional Ofd1 deficient mouse models (Ksp and IND), 
which resulted in viable mice characterized by renal cystic disease and progressive impairment of renal function. 
The study of these models allowed us to demonstrate that primary cilia initially form and then disappear after the 
development of cysts, suggesting that the dysfunction of primary cilia is a consequence rather than the primary 
cause of renal cystic disease. Immunofluorescence and western blotting analysis revealed upregulation of the 
mTOR pathway in both dilated and non dilated renal structures. Treatment with rapamycin, a specific inhibitor of 
the mTOR pathway, resulted in a significant reduction in the number and size of renal cysts and a decrease in the 
cystic index compared with untreated mutant animals, suggesting that cystogenesis in our model is mTOR-
dependent. mTOR is frequently deregulated in inherited forms of cystic kidney although the molecular 
mechanisms underlying this phenomenon are still to be determined. The use of both in vitro and in vivo systems 
allowed us to demonstrate that OFD1 has a role in the formation of the pre-initiation complex of translation (PIC). 
We showed that OFD1 coimmunoprecipitates with two subunits (η and δ) of the eIF3 complex and colocalizes at 
the centrosome with subunits of the PIC. In addition, we also demonstrated that OFD1 is present in polysomes 
extracted from kidneys and interacts in vivo with subunits of the eIF3 complex. Microarray experiments performed 
on mRNA extracted from polysomes indicate impaired translation for a number of transcripts. These results 
indicate for the first time a role of OFD1 in the formation of the PIC and in the regulation of translation. Among 
the putative targets we focused our attention on GH and our data suggest that higher levels of the GH due to the 
impairment of translation may be responsible for the upregulation of the mTOR pathway. 
All together our results shed light on the pathogenetic mechanisms underlying this rare inherited form of renal 
cystic disease and propose new possible link between renal cystic disease and deregulation of the mTOR pathway. 
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INTRODUCTION  
1. The molecular basis of OFDI syndrome 
1.1. Clinical features observed in OFDI syndrome 
Oral-facial-digital type I (OFDI; MIM 311200) syndrome is an X-linked dominant male lethal disorder and 
belongs to the heterogeneous group of developmental disorders known as Oral-facial-digital syndromes (OFDs) 
(Toriello 1993) (Gurrieri, Franco et al. 2007). OFDI syndrome was reported in 1954 (Papillon and Psaume 1954) 
and further defined by Gorlin and Psaume in 1962 (Gorlin and Psaume 1962). OFDI has an estimated incidence 
of 1:250,000 live births (Wahrman, Berant et al. 1966) and it has been described in different ethnic backgrounds 
(Salinas, Pai et al. 1991). This syndrome is transmitted as an X-linked dominant condition with embryonic male 
lethality, which usually occurs in the first and/or second trimester of pregnancy (Doege, Thuline et al. 1964; 
Wettke-Schafer and Kantner 1983). However, 75% of the cases are apparently sporadic. OFD type I, similar to all 
other OFDs, is characterized by malformations of the face, oral cavity and digits with a high degree of phenotypic 
variability. The central nervous system is frequently involved. Dysmorphic features affecting the head and face 
include facial asymmetry, hypertelorism, micrognathia, broadened nasal ridge, hypoplasia of the malar bone and 
of the nasal cartilage, and frontal bossing (Gorlin 2001). Craniofacial abnormalities include facial anomalies in 
69.1% of cases (downslanting palpebral fissures, hypoplasia of the ala nasi, hypertelorism, telecanthus, 
microretrognathia, epicanthus, flat face, and low-set ears); evanescent milia (29.4%) of the face and ears, which 
usually disappear before the third year of life; and dryness, brittleness, and/or alopecia of the scalp hair (21.5%). 
Also, cleft lip and pseudocleft of the upper lip are observed in 32.6% of patients (Table I). Oral abnormalities are 
consistently reported in this condition and include oral aberrant frenula (63.7%), tongue abnormalities (84.1%) 
(lobulated tongue, lingual hamartomas, clefts), clefts of the alveolar ridge (22.2%), cleft/high arched palate 
(49.6%), and teeth abnormalities (43.3%) (Table I) (Macca and Franco 2009). These clinical features overlap 
with those reported in the other forms of OFDs (Toriello 1993), although among these, OFDI can be easily 
distinguished because of its X-linked dominant inheritance pattern and because of the renal cystic disease, which 
is specific to type I (Connacher, Forsyth et al. 1987; Donnai, Kerzin-Storrar et al. 1987; Scolari, Valzorio et al. 
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1997).  Examples of the clinical signs observed in OFD type I are reported in Figure 1. Histochemical analysis of 
cystic renal tissues from OFDI patients demonstrate a predominantly glomerulocystic kidney disease with a minor 
population of tubular cysts (Feather, Winyard et al. 1997). The age of onset of cystic disease in patients with 
OFDI is most often adulthood (second and third decades) but cysts have been occasionally described in children 
in the first decade (Stapleton, Bernstein et al. 1982; Salinas, Pai et al. 1991; Odent, Le Marec et al. 1998). The 
overall incidence of renal cysts in this condition is 37.3%, if we consider all patients regardless their age (Table 
I). However, if we consider the subset of cases >18 years this incidence goes up to 63%, thus indicating that most 
cases are detected in adulthood due to both the delayed age of onset and to more frequent monitoring of the renal 
function. Systematic monitoring from early years could reveal that cystic kidney disease is more frequent than 
previously estimated in this condition. This observation represents a strong indication for renal function 
monitoring (both morphological and biochemical) in OFDI patients from childhood (Prattichizzo, Macca et al. 
2008). 
 
1.2. The Identification of the gene responsible for OFD type I syndrome  
The locus of OFD type I was first mapped by linkage analysis to the Xp22 region (Feather, Winyard et al. 1997; 
Gedeon, Oley et al. 1999). The gene responsible for this rare genetic disorder, named OFD1, was identified by 
using a positional candidate gene approach in 2001 (Ferrante, Giorgio et al. 2001). The OFD1 gene comprises 23 
exons encoding a 1011 amino acid protein that shares no sequence homologies with proteins of known function. 
Interestingly, the OFD1 gene has been found to escape X-inactivation in human while the murine counterpart is 
subject to X-inactivation (Ferrante, Barra et al. 2003). A total of 67 different mutations in OFDI patients have 
been reported to date, including frameshifts, splicing, non-sense and missense mutations. The vast majority is 
represented by frameshift mutations resulting in premature protein truncation (Ferrante, Giorgio et al. 2001; 
Rakkolainen, Ala-Mello et al. 2002; Romio, Wright et al. 2003; Thauvin-Robinet, Cossee et al. 2006; Prattichizzo, 
Macca et al. 2008). Most of the OFD1 mutations identified to date in patients lead to a premature truncation of the 
protein in its N-terminal region and are therefore predicted to act with a loss of function mechanism. However, the 
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possibility that truncated forms of the OFD1 protein may have a dominant-negative effect on the wild type protein 
has not been formally ruled out.  
The OFD1 transcript has been shown to be expressed in both human and murine structures in all tissues affected 
by the disorder from early stages of development to adulthood. Studies have shown that OFD1 is expressed in all 
adult human tissues examined (pancreas, kidney, skeletal muscle, liver, lung, placenta, brain, and heart)(de 
Conciliis, Marchitiello et al. 1998). In the laboratory were I completed my PhD project, RNA in situ studies on 
mouse-embryo tissue sections at different developmental stages starting from E12.5 were performed to investigate 
the spatiotemporal expression of the Ofd1 transcript during development. The first site of expression was sharply 
and exclusively detected at 12.5 days of gestation in the genital ridges. At later stages (E14.5 and E16.5), Ofd1 
expression is not only confined in the developing gonads, but high to moderate levels of expression are detected in 
various craniofacial structures and in the nervous system. In particular, Ofd1 resulted to be highly expressed in the 
epithelium lining the oral and nasal cavities, including the tongue and the gum region, in the developing tooth 
buds, in the Rathke’s pouch (primordium of the adenohypophysis), and in the vibrissae follicles. The transcript is 
also highly represented in the proliferative and postmitotic layers of the cerebral cortex and ganglionic eminences 
(anlage of the basal ganglia), the neural retina, the inner ear, and the dorsal root ganglia and the kidneys (Ferrante, 
Giorgio et al. 2001). Concerning the expression of the Ofd1 transcript in the kidney immunohistochemical studies 
demonstrated that the Ofd1 protein localizes in the fetal developing metanephros, in particular in the outer 
nephrogenic zone of the cortex in the mesenchyme. Minimal positive signal was detected in later nephron 
precursors, including vesicles, comma, and S-shaped bodies. Consistent staining was not observed in developing 
glomeruli (Romio, Wright et al. 2003) even if a glomerular function for Ofd1 was demonstrated using different 
animal models, namely the mouse (see below) (Ferrante, Zullo et al. 2006) and the zebrafish (Ferrante, Romio et 
al. 2009). 
 
1.3. The OFD1 protein: putative functions and subcellular localization 
The OFD1 gene encodes a 1011 amino acid protein, which shares no sequence homologies with proteins having 
known function. Five predicted coiled coil domains (hereafter CC) occupy almost the entire length of the molecule 
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(de Conciliis, Marchitiello et al. 1998) whereas the N-terminal region shares a Lis1 homology motif (LisH) with 
over 100 eukaryotic intracellular proteins (Emes and Ponting 2001). Several studies indicate that the alpha-helical 
CC, is a highly versatile folding motif found in proteins with different functions and is described to mediate 
subunit oligomerization (Burkhard, Stetefeld et al. 2001). The biological function of the LisH motif is still 
unknown, although it has been postulated to be involved in cell migration, nucleokinesis, and chromosome 
segregation (Emes and Ponting 2001).  
Previous studies had shown that OFD1 co-localizes with γ-tubulin and is a centrosome-associated protein (Romio, 
Wright et al. 2003). Data from different laboratories also indicate that OFD1 localizes to the basal body of primary 
cilia in fully differentiated renal epithelial cells and in MDCK (Madin-Darby Canine Kidney Cells) (Figure 2 B 
and C) (Romio, Wright et al. 2003; Giorgio, Alfieri et al. 2007). In addition, it was recently described that OFD1, 
is a component of the distal centriole in the centrosome and controls centriole length and building (Singla, 
Romaguera-Ros et al. 2010). The centrosome is an organelle that serves as the main microtubule organizing center 
(MTOC) of the animal cell as well as a regulator of cell-cycle progression. Moreover, centrosomes can act as basal 
body at the cell cortex, promoting cilia assembly and function. The centrosome and the primary cilium are 
strongly linked both structurally and functionally; a consistent number of centrosomal proteins were found to 
localize to the centrosome, the basal body and the ciliary axoneme during different phases of the cell cycle.  
In addition data generated in the laboratory when I performed my PhD project also demonstrated a nuclear 
localization for the OFD1 protein (Figure 2 F, G and H) (Giorgio, Alfieri et al. 2007). In the same report Giorgio 
G. and coauthors also demonstrated that OFD1 is able to self-associate through its CC rich region and it interacts 
with RuvBl1. RuvBl1 belongs to the AAA-family of ATPases, is involved in transcriptional regulation and cell 
division and it has been associated to ciliary assembly and function in Chlamydomonas reinhardtii (Stolc, 
Samanta et al. 2005). OFD1, together with RuvBl1, is also able to coimmunoprecipitate with subunits of the 
human TIP60 histone acetyltransferase (HAT) multisubunit complex, suggesting that OFD1 may be part of a 
multi-protein complex and could play different biological functions in the centrosome-primary cilium organelles 
as well as in the nuclear compartment (Giorgio, Alfieri et al. 2007). 
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2. Animal models for OFDI syndrome 
2.1. Generation of a null murine model for OFDI syndrome 
To gain insights into the pathogenetic mechanisms underlying OFDI syndrome, a murine animal model for this 
condition was generated in Prof Brunella Francos’s laboratory (Ferrante, Zullo et al. 2006). Exons 4-5 of the Ofd1 
murine homolog were cloned between two loxP sites. The Ofdfl line was crossed with pCX-NLS-Cre mice, a 
generale deletor cre line that expresses the Cre recombinase ubiquitously starting at the four-cell-stage (Nagy 
2000). This cross would allow to obtain null mice with ubiquitous Ofd1 inactivation from early stages of 
development. Exicision of these exons by a cre/loxP strategy resulted in the generation of a shorter, presumably 
non-functional form, of 106 AA. This strategy was selected to reproduce the pathological condition observed in 
humans since many non-sense or frameshifts mutations leading to the production of a short and truncated form of 
the protein have been identified in exon 3 in OFDI patients. Heterozygous females (Ofd1∆4-5/+), reproduced the 
main features of the human disease, albeit with increased severity, probably due to differences between the X-
inactivation patterns observed in human and mouse (Ferrante, Barra et al. 2003; Morleo and Franco 2008). Female 
mutants died at birth, displaying craniofacial and skeletal abnormalities including polydactyly or polysyndactyly, 
with seven to nine digits. The tibia and fibula in the hindlimb were invariably bent and in some cases fused and 
additionally, abnormalities of the ribs and of the sternum, which was not fused along the midline have been 
observed (Ferrante, Zullo et al. 2006).  
Autopsy of the newborn Ofd1∆4-5/+ females showed also disorganization of the brain, reduction of the lungs, 
defects in the great vessels and a highly penetrant renal cystic disease of glomerular origin  (Figure 3).  
Immunofluorescence analysis with an antibody that preferentially labels the ciliary axoneme of primary cilia 
showed the absence of cilia on the luminal surfaces of cells that lined the cysts, thus implicating ciliogenesis as a 
mechanism underlying cyst development in OFD type I (Figure 3 F). Cilia were present in noncystic glomeruli 
and in normal tubules adjacent to the cysts (arrows in Figure 3 F); due to the fact that heterozygous females are 
mosaics and for the X inactivation phenomenon we have the presence of both cells expressing the mutated X and 
cells expressing the normal X chromosome (Ferrante, Zullo et al. 2006).  
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Complete inactivation of Ofd1 in hemizygous males (Ofd1∆4-5) causes male embryonic lethality, as the majority of 
Ofd1∆4-5 male embryos die by E12.5, and early developmental defects, mainly neural tube, heart and laterality 
defects were observed. Some Ofd1∆4-5 male embryos display situs inversus and abnormal expression of the 
asymmetrical markers Nodal and Pitx2 at E8 suggesting that heart position is randomized due to loss of molecular 
asymmetry. In addition, electron microscopy analysis demonstrated absence of primary cilia in the embryonic 
node of these embryos at E7.5 (Ferrante, Zullo et al. 2006). 
These results are consistent with the subcellular localization of OFD1 in the basal body and indicate that Ofd1 is 
required for primary cilia formation and left right axis specification (Ferrante, Zullo et al. 2006). In addition these 
results demonstrate that OFD type I syndrome should be included in the growing number of disorders associated 
to ciliary dysfunction. 
 
2.2. Generation and characterization of model for OFD type I syndrome in zebrafish 
Recently Ofd1 function was also studied in developing zebrafish (Danio rerio) embryos (Ferrante, Romio et al. 
2009). The Zebrafish homolog, ofd1, encodes a protein with a LisH domain and coiled-coil domains with a 29.6% 
identity with the human OFD1. Transcription of ofd1 occurs ubiquitously in embryos with noticeably higher levels 
in ciliated organs such as otic vesicles and neuromasts and the protein has the same centrosome/basal body 
localization previously described in human and mice. Injection of antisense morpholinos (MOs) in one-cell stage 
embryos, determines a typical ciliary phenotype with bent body, laterality defects and oedema. In this model, cilia 
are shorter then normal and show an altered ultrastructure leading to an alteration of the fluid flow and laterality 
defects as a consequence. Interestingly, they show a role for ofd1 in convergent extension (CE) during 
gastrulation, consistent with other studies linking cilia and non-canonical, PCP, Wnt signalling (Benzing, Simons 
et al. 2007; Corbit, Shyer et al. 2008). This could be an indirect result of a requirement for Ofd1 in normal ciliary 
structure and function, or could occur directly through interaction with Wnt signalling components, further 
analysis are necessary to address this point. However, while cystic disease was not observed, the described CE 
defects could be responsible also for delayed glomerular fusion observed in ofd1 morphants. In addition, 
glomerular vascolarization is also compromised (Ferrante, Romio et al. 2009). Very little is known about a 
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glomerular function for ofd1 and the paper by Ferrante et al., opens new insights in renal involvement for the 
protein. Altogether the phenotype observed in the zebrafish model together with the phenotype described in the 
null murine model indicate that Ofd1 plays an important role in the pathogenesis of inherited renal cystic disease 
and in normal renal function. 
 
3. Renal cystic disease: genetic causes and pathogenetic mechanisms  
3.1.  Introduction and definition  
Renal cystic disease is a pathological condition characterized by the growth of numerous cysts in the kidneys. The 
cysts are filled with fluid and can replace much of the mass of the kidneys, reducing kidney function and leading 
to end stage renal failure with indication for dialysis or renal transplantation. One third of people older than 50 
years develop renal cysts with multiple aetiologies:  
• Genetic diseases in which renal cyts are the prevalent clinical sign – Autosomal recessive polycystic 
kidney disease (ARPKD), Autosomal dominant polycystic kidney disease (ADPKD), nephronophthisis 
(NPHP), medullary cystic kidney disease (MCKD), glomerulocystic kidney disease (GCKD). 
• Cysts associated with systemic genetic disease – Autosomal Dominant syndromes: Von Hippel-Lindau 
syndrome (VHLS), tuberous sclerosis (TS) – Autosomal Recessive syndromes: Meckel’s Syndrome; 
Jeune’s Asphyxiating Thoracic Dystrophy; Zellweger’s Cerebrohepatorenal Syndrome; Ivemark’s 
Syndrome (renal-hepatic-pancreatic dysplasia); Bardet-Biedl Syndromes – X linked syndromes: Oro-facio-
digital type I syndrome (OFDI).  
• Acquired – Simple cysts, acquired cystic renal disease, medullary sponge kidney (MSK). 
• Malignancy – Cystic renal cell carcinoma (RCC). 
Among the genetic forms of Polycystic Kydney diseases (PKDs), ADPKD is the most common and occurs in 1 in 
800 live births. Two genes have been identified for ADPKD: PKD1 and PKD2. These genes encode for two-
membrane proteins polycistin 1 (Pc1) and 2 (Pc2), respectively. Pc1 is a mechanoreceptor localized at focal 
adhesions, cell-cell junctions and primary cilia and transduces signals through phosphorylation cascades to 
regulate cell transcription (Zhou 2009). Pc1 interacts with Pc2, a calcium-permeable channel that facilitate 
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calcium influx. Calcium acts as an intracellular second messanger and activates G proteins and the production of 
cAMP leading to the regulation of multiple signaling pathways (Chapin and Caplan 2010). ARPKD is quite rare 
and is caused by mutations in the PKHD1 gene encoding for Fibrocystin. This protein is a membrane receptor that 
is highly espressed in fetal-kidney collecting ducts and it is now firmly established that localizes at the primary 
cilium (Ward, Yuan et al. 2003). In addition, NPHP is caused by mutations in twelve genes (NPHP1–11 and 
NPHPL1). The first identified NPHP gene was NPHP1 that encodes the protein nephrocystin-1, which is mutated 
in approximately 20% of all cases of NPHP (juvenile NPHP type 1 form) (for a review on nephronophtisis see 
(Hurd and Hildebrandt 2011). Unlike the Polycystins and Fibrocystin, Nephrocystin is a small protein that does 
not localize at the membrane, however it localizes at the focal adhesions and at the primary cilium (Donaldson, 
Dise et al. 2002; Wilson 2004; Fliegauf, Horvath et al. 2006). Also the other proteins associated to NPHP localize 
at the cilium (Hurd and Hildebrandt 2011). It is interesting to note that despite the clinical differences in the onset 
of cysts, the portion of the nephron involved and the prognosis, all these proteins show common subcellular 
localizations and recently a physical interaction between Pc1 and NPHP1 has been described, suggesting a 
common role in the cell. These observations suggest that common mechanisms may underlie the formation and 
enlargement of renal cysts. As reviewed in Wilson 2004 different biological processes are involved in renal 
cystogenesis. A precisely controlled balance between cellular proliferation and cell death (apoptosis) is essential 
for normal growth and differentiation of the kidney and maintenance of normal renal structure after birth. These 
fundamental processes are disturbed in PKDs stimulating growth of cysts. An increase of cell proliferation is 
described in all forms of PKD and one possibility is that the higher amount of calcium influx activates the MAP 
Kinase pathway (Calvet and Grantham 2001; Zhou 2009). In addition, persistence of apoptosis, due to inactivation 
of apoptotic inhibitors observed in models for genetic forms of PKD, can destroy much of the normal parenchyma 
allowing cystic epithelia to proliferate. Another alteration commonly linked to PKD is fluid accumulation due to 
dysregulation or altered transcription of ion-transporters (Terryn, Ho et al. 2011), such as aquaporins. As 
described before, proteins involved in genetic forms of PKD localize at focal adhesions (FAK). Several 
experiments have shown that inactivation of different matrix adhesion receptors and FAK complexes causes 
formation of the cysts, probably because cells in PKDs are more adherent to matrixes causing defects in migration 
required for the normal morphogenesis of the kidney. Alteration in proliferation and FAKs determine also loss of 
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cell polarity in renal epithelial cells with consequent mislocalization of several proteins and impairment of 
orientation during cell divisions (Gibson, Veldhuis et al. 2011). Many signalling underline these biological 
processes that was deregulated by mutations in the genes involved in PKDs. 
 
3.2. Molecular mechanisms of cystogenesis  
Genes leading to PKDs were extensively studied in the last years and, even if the exact mechanisms that result in 
cysts development are not well clarified, these genes seem to be involved in the regulation of different intracellular 
signallings controlling cell proliferation, apoptosis and cell adhesion. 
In a recent review by Hannah C. Chapin and Michael J. Caplan (Chapin and Caplan 2010) the more recent insights 
in the signalling pathways modified by Pc1 and Pc2 were reported (Figure 4). To summarize broadly, the 
evidence highlights three general themes in the relationship between the Pc1 and Pc2 proteins and cellular 
signalling pathways: negative growth regulation, G protein activation, and Wnt pathway modulation. Elevated 
cellular growth rates are a hallmark of PKDs, so it is no surprise that the polycystin proteins negatively regulate 
cellular growth and division through several pathways. One significant effect of PC1 involves inhibition of the 
mTOR (mammalian target of rapamycin) cascade. PC1 decreases mTOR activity by stabilizing the functional 
TSC1–TSC2 complex, a known inhibitor of the mTOR pathway. PC1 decreases ERK-dependent phosphorylation 
of TSC2 at S664 (Distefano, Boca et al. 2009), which allows TSC2 to remain bound to TSC1 (Ma, Chen et al. 
2005). The TSC1/2 complex is also stabilized by the binding of PC1 to TSC2 at the plasma membrane, protecting 
TSC2 from phosphorylation by Akt at S939. Cell cycle progression is also governed by cyclin-dependent kinases 
(Cdks), and p21 slows or halts cell cycle progression by inhibiting Cdk2. The polycystin proteins act in concert to 
positively regulate p21 expression and activity. PC1 can increase p21 levels by binding and activating members of 
the Janus kinase (JAK) and signal transducers and activators of transcription (STAT) pathway, thus elevating p21 
levels and decreasing cell growth. This activation requires a PC2-dependent interaction with JAK2 (Bhunia, 
Piontek et al. 2002). In addition, Pc1 has a direct role in activating G proteins. G protein α-subunits activated by 
PC1 go on to positively regulate the activity of the c-Jun N-terminal kinase (JNK) and the AP-1 transcription 
factor (Parnell, Magenheimer et al. 2002). AP-1 controls differentiation, apoptosis, and proliferation through a 
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complex network of signaling and binding proteins (Shaulian and Karin 2002). The interaction between PC1 and 
G proteins also activates the nuclear factor of activated T cells (NFAT) that is also connected to PC2 dependent 
calcium influx. NFAT is activated by calcineurin, which, in turn, is activated by sustained elevation of cytosolic 
Ca2+ levels. Activated calcineurin dephosphorylates NFAT, leading to its nuclear accumulation. The NFAT 
pathway regulates genes involved in apoptosis, growth, cellular differentiation, and cell adaptation (Horsley and 
Pavlath 2002). Finally, PC1 seems to have a profound influence on both the canonical (β-catenin dependent) and 
noncanonical (β-catenin independent) components that make up the Wnt signaling network. In the canonical 
pathway, the presence of the Wnt ligand induces β-catenin stabilization and nuclear translocation, leading to 
transcriptional activity. Cleaved PC1 inhibits this pathway by directly or indirectly binding to β-catenin, moving 
with it to the nucleus, and reducing its ability to promote transcription (Lal, Song et al. 2008). PC1 may also 
regulate noncanonical Wnt signaling, which is in turn related to the maintenance of planar cell polarity. The cells 
lining renal tubules generally divide parallel to the tubule’s axis, lengthening the tubule rather than expanding its 
diameter. Tubule-lining cells in models of polycystic kidney disease, however, show a tendency to divide at an 
angle to the tubule’s axis, which could lead to expansion of the tubule diameter. This deviation can occur before 
cysts appear, suggesting that a loss of this planar cell polarity may be a precursor to cyst formation (Fischer, 
Legue et al. 2006; Patel, Li et al. 2008). Is interesting to note that Pc1 and Pc2 such as Nephrocystin 1 and almost 
all proteins encoding transcripts that when mutated cause renal cystic disease localize at the primary cilium. This 
organelle, which is described in greater detail in the next paragraph, is like an antenna for the cells, senses the 
extracellular environment and transduces signals inside the cells. Interestingly, mutations in proteins involved in 
cilia formation and maintenance cause genetic syndromes with common phenotypes, for this reason these group of 
syndromes are called ciliopathies. One of the main features of ciliopathies, as further discussed in the next section, 
is the renal cystic disease. This observation suggests an important role for the primary cilium in the formation 
and/or expansion of renal cysts. 
 
 19 
3.3. Primary cilium in physiological and pathological conditions 
The primary cilium is an organelle protruding from the cell that consists of a basal body located under the cell 
surface and a projecting structure called the axoneme. The basal body comprises two centrioles embedded in the 
pericentriolar material, while the ciliary axoneme contains 9 doublets of microtubules surrounded by a membrane 
contiguous with the plasma membrane (Satir and Christensen 2007; Satir, Pedersen et al. 2010; Seeley and 
Nachury 2010). Its peculiar structure is called “9 + 0” for the absence of the central pair of microtubles normally 
present in motile cilia (“9 + 2” structure) (Figure 5 A) (Davenport and Yoder 2005). The inner microtubule pair 
could be required for back-and-forth movement while in its absence the cilia movement is rotational. Therefore, 
the primary cilium is considered to be a non-motile organelle. The unique 9 + 0 motile cilium is present on the 
embryonic node. The specific feature of the 9 + 0 motile cilium is its rotational movement that generates a 
leftward flow of extraembryonic fluid in the nodal area (Nonaka, Tanaka et al. 1998; Hirokawa, Tanaka et al. 
2009). Moreover, a 9+4 structure for motile cilia was also described in the notochordal plate of rabbit embryos 
(Feistel and Blum 2006). 
The primary cilium only assembles when cells exit the cell cycle from mitosis, and it is considered to be an 
organelle of cells in the quiescent or differentiated state. In fact, the cell cycle is preceded by cilium reabsorption 
(Quarmby and Parker 2005). The primary cilium is a highly dynamic organelle both because it is assembled only 
during specific phases of the cell life and because active molecular transport occurs within its axoneme. Given the 
dynamism of the organelle, ciliogenesis should be tightly regulated, and many modulators have been recently 
identified by a functional genomic screen (Kim, Lee et al. 2010). Primary cilia are present on a wide variety of cell 
types and tissues (Figure 5 B-D), such as the kidney tubule, the bile duct, neurons, the endocrine pancreas, the 
thyroid, smooth muscle cells, fibroblasts and others (for a complete list of cells and tissues containing cilia: 
http://www.bowserlab.org/primarycilia/cilialist.html). 
As I stated above, alterations in the structure or function of primary cilia are responsible for a group of diseases 
known as ciliopathies. As cilia are a component of almost all cells, ciliary dysfunction can manifest as a wide 
constellation of features that include renal and hepatic cysts, malformations of the central nervous system (CNS), 
polydactyly and other skeletal defects, retinal degeneration, and obesity (Badano, Mitsuma et al. 2006; D'Angelo 
and Franco 2009; Lancaster and Gleeson 2009) (Figure 6). These phenotypes are quite peculiar of ciliopathies and 
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recent experimental evidences also suggest a tissue-specific function of primary cilia (Goetz and Anderson 2010; 
D'Angelo and Franco 2011). Mutations in over 40 genes to date have been associated with ciliopathic features 
(Waters and Beales 2011). However, with over 1,000 polypeptides currently identified within the ciliary proteome, 
several other disorders associated with this constellation of clinical signs will likely be ascribed to mutations in 
other ciliary genes. Genes that are mutated in ciliopathies can affect ciliary signalling in different ways: through 
changes in cilia structure or in targeting signalling molecules appropriately. As reviewed in Bettencourt-Dias et 
al., 2011 (Bettencourt-Dias, Hildebrandt et al. 2011), different pathways are involved in ciliopathies. Changes in 
the Hh pathway are associated with several developmental defects, including polydactyly, neural tube and 
craniofacial defects. Mouse mutants deficient in specific genes involved in intraflagellar transport (IFT), including 
the kinesin family member 3A (Kif3a), exhibit Hh mutant phenotypes with cystic kidneys. In addition, several 
molecules associated with cilia-related diseases, play a role in the Wnt pathway. For instance, Inversin/NPHP2 
function is necessary to switch from the canonical to the non-canonical Wnt/planar cell polarity (PCP) pathway. 
Moreover, several BBS proteins cooperate with non-canonical Wnt signalling in PCP. There is aberrant 
orientation of the mitotic spindle in mouse or rat models with mutation of the cystic kidney disease genes 
hepatocyte nuclear factor 1 (Hnf1), Pkhd1 and Kif3a, suggesting that defective spindle orientation could contribute 
to kidney cysts. The role of proliferation in the genesis of ciliopathies phenotypes is supported by the fact that the 
cyclin-dependent kinase inhibitor roscovitine can efficiently treat two renal cystic mouse models (jck and cpk) 
(Chang and Ong 2011). It is not clear whether all ciliopathies phenotypes result from dysfunctional ciliary 
signalling or whether, in some cases, impairment of the centrosome signalling and/or cytoskeleton disorganisation 
alone trigger the disease and display dysfunction of cilia as a consequence. 
 
3.4. Primary cilium and renal cystic disease 
Primary cilia are present on the epithelial cells of renal tubules, and their dysfunction is very often associated to 
cystic disease (Wilson 2004; Deltas and Papagregoriou 2010). Cystic kidney disease is a common feature of 
pleiotropic disorders such as Bardet–Biedl (BBS), Joubert (JBTS), Meckel–Gruber, Oral-facial-digital type I 
(OFDI), and Senior–Loken syndromes. Accordingly, all the protein products encoded by the genes responsible for 
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the above mentioned inherited forms of cystic kidneys disease are expressed in primary cilia, basal bodies, or the 
centrosome (Yoder 2007). Ciliary localization is also described for proteins involved in genetic forms of PKD, 
such as ADPKD, ARPKD and JNPHP, as described in the previous paragraph. Numerous mouse models have 
revealed kidney polycystic disease to be associated to the dysfunction of primary cilia (Wilson 2008), although the 
underlying molecular mechanisms are still undetermined.  
In the kidney, primary cilia have a mechano-sensory role sensing flow (Praetorius and Spring 2005). Bending of 
the renal primary cilium initiates a calcium-signaling pathway that is dependent on the ciliary proteins Pc1 and 
Pc2 (Nauli, Alenghat et al. 2003). In response to fluid flow, the C-terminal tail of the plasma membrane Pc1 is 
proteolytically removed and the protein translocates to the nucleus where it directly initiates signaling processes 
linked to proliferation (Chauvet, Tian et al. 2004). In addition to their mechano-sensory role, renal primary cilia 
contain components of the Wnt pathway that plays an important role during kidney development (Simons, Gloy et 
al. 2005). Little is known about the role of renal primary cilium during postnatal life.  
The main processes involved in renal cyst formation are defects in proliferation, differentiation, matrix adhesion, 
or polarity (Yoder 2007; Lee, Battini et al. 2011) and more and more evidence link dysfunction of primary cilia to 
deregulation of different pathways (Winyard and Jenkins 2011). However, ciliary disfunction is unlikely to be the 
only cause of cystic kidneys (Winyard and Jenkins 2011). Actually, it was reported that non-ciliary proteins give 
rise to renal cystic disease when mutated. In particular Bicaudal C is a conserved RNA-binding protein that is 
mutated in two murine models for renal cystic disease, the jcpk and bpk models (Cogswell, Price et al. 2003). 
Moreover, recent ﬁndings link the activity of this RNA-binding protein with the orientation of cilia via Wnt 
signaling (Maisonneuve, Guilleret et al. 2009). Another example is the FLCN protein, also known as folliculin. 
Mutations in the BHD/FLCN gene cause the Birt – Hogg – Dube syndrome characterized by renal cystic disease 
and increased risk for renal neoplasia. The gene product localizes to the cytoplasm and the nucleus and seems to 
be involved in the regulation of the mTOR pathway (Chen, Futami et al. 2008; Hasumi, Baba et al. 2008; Hasumi, 
Baba et al. 2009). Even if there is a clear link between ciliary alterations and renal cystic disease, further studies 
are necessary to address the causal link between cysts development and ciliary functions. 
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4. The mTOR pathway  
 
4.1. The mTOR pathway and the translational machinery  
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and belongs to the 
phosphatidylinositol 3-kinase-related kinase protein family. mTOR regulates cell growth, cell proliferation, cell 
motility, cell survival, protein synthesis and transcription (Beevers, Li et al. 2006; Sonenberg and Pause 2006). It 
integrates the input from upstream pathways, including insulin, growth factors and amino acids (Sonenberg and 
Pause 2006). mTOR also senses cellular nutrient and energy levels and redox status (Tokunaga, Yoshino et al. 
2004). The mTOR protein can exists in two different complexes: mTOR Complex 1 (mTORC1) and mTOR 
Complex 2 (mTORC2). The mTORC1 complex includes mTOR, the regulatory-associated protein of mTOR 
(Raptor), the mammalian LST8/G-protein β-subunit like protein (mLST8/GβL) and other partners (Kim, 
Sarbassov et al. 2002; Kim, Sarbassov et al. 2003). This complex works as a nutrient/energy/redox sensor and 
controls protein synthesis. Among the targets of mTORC1, p70-S6 Kinase 1 (S6K1) and the eukaryotic initiation 
factor 4E binding protein 1 (4E-BP1) have been extensively studied (Sonenberg and Pause 2006) (Figure 7 A). 
The mTORC2 complex, instead, is composed by mTOR, the rapamycin-insensitive companion of mTOR (Rictor), 
GβL, and the mammalian stress-activated protein kinase interacting protein 1 (mSIN1) (Sarbassov, Ali et al. 2004; 
Frias, Thoreen et al. 2006). mTORC2 is an important regulator of the cytoskeleton through its stimulation of F-
actin stress fibers, paxillin, RhoA, Rac1, Cdc42, and protein kinase C α (PKCα)(Sarbassov, Ali et al. 2004). In 
order to execute its function, mTORC2 phosphorylates the serine/threonine protein kinase Akt/PKB and appears 
to be regulated by insulin, growth factors, serum, and nutrient levels (Frias, Thoreen et al. 2006). Originally, 
mTORC2 was identified as a rapamycin-insensitive entity, as acute exposure to rapamycin did not affect 
mTORC2 activity or Akt phosphorylation (Sarbassov, Guertin et al. 2005) (Figure 7 B). 
Translation of an mRNA into its protein is accomplished in three successive steps (initiation of translation, 
elongation of the native peptide and termination) controlled by a wide range of regulatory factors. During 
initiation of translation, the tRNA for the Methionine (Met-tRNA) together with the small ribosomal subunit (40S) 
and eukaryotic initiation factors (eIFs), form a complex onto the mRNA. By doing so, the reading frame for the 
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protein is determined and the assembled ribosome can start elongation, which is regulated by elongation factors 
(EFs), by adding amino acids to the growing peptide chain in accordance with the mRNA sequence (Browne and 
Proud 2002; Frank 2003; Thornton, Anand et al. 2003). The termination phase begins after recognition of a stop 
codon. Subsequently, the 80S ribosome is released from the protein and dissociates into its subunits to be recycled 
in another round of peptide synthesis (Van Der Kelen, Beyaert et al. 2009).  
The mTOR pathway plays a role in the phosphorylation of a number of components of the translation machinery. 
mTOR signaling appears to be important for both short-term (minutes) and long-term (hours) induction of 
translation by increasing the levels and activation of ribosomes and translational factors (Dennis, Jaeschke et al. 
2001). Upon activation, S6K1 can in turn stimulate the initiation of protein synthesis through phosphorylation and 
thus activation of S6 Ribosomal protein (a component of the ribosome) and other components of the translational 
machinery (Raught, Peiretti et al. 2004; Holz, Ballif et al. 2005; Shahbazian, Roux et al. 2006) and recent reviews 
on this topic (Ma and Blenis 2009; Van Der Kelen, Beyaert et al. 2009). Moreover, non-phosphorylated 4E-BP1 
binds tightly to the translation initiation factor 4E (eIF4E), preventing it from recruiting to the ribosomal initiation 
complex. Upon phosphorylation by mTORC1, 4E-BP1 releases eIF4E, allowing it to perform its function 
(Schalm, Fingar et al. 2003). Figure 8 shows in details the events leading to initiation of translation. mTOR binds 
the eukaryotic initiation factor 3 (eIF3) after aminoacids stimuli and exposure to nutrients and their binding is 
prevented by rapamycin. After this binding, mTOR is able to phosphorylate both S6K and 4E-BPs. 
Phosphorylated S6K dissociates from eIF3 and activates S6 ribosomal protein. After this phosphorylation event, 
the 40S ribosomal subunit is recruited by eIF3 (Holz, Ballif et al. 2005). In addition, phosphorylated 4E-BP1 
dissociates from eIF4E, allowing the recruitment of eIF4G, eIF4B and eIF4A to the 5′ end of an mRNA. Finally, 
eIF3, the small ribosomal subunit (40S) and the ternary complex (comprising eIF2, Met­tRNA and GTP) are 
recruited to the cap, resulting in the assembly of the 48S translation pre­initiation complex, ribosome scanning and 
translation initiation (Ma and Blenis 2009). More than one ribosome can translate an mRNA at one time, making it 
possible to produce many polypeptides simultaneously from a single mRNA. The mRNA molecule bound by a 
cluster of ribosomes are called polyribosomes (or polysomes) and were first discovered and characterized by 
Jonathan Warner, Paul Knopf, and Alex Rich in 1963. The mTOR pathway was associated with an increase of 
polysomes due to its role in translation. Deregulation of the mTOR pathway has been demonstrated in 
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pathological conditions including cancer (Beevers, Li et al. 2006) and, more recently, in polycystic kidney disease 
(Lieberthal and Levine 2009). 
 
4.2. The mTOR pathway and cell cycle in renal cystic disease 
The mammalian target of rapamycin (mTOR) is a key regulator of cell growth and proliferation. The mTOR 
pathway integrates signals from nutrients, energy status and extracellular growth factors to regulate translation of 
many proteins involved in cell cycle progression, angiogenesis, ribosome biogenesis, and metabolism. Growth 
factors such as insulin-like growth factor, epidermal growth factor and vascular endothelial growth factor bind to 
and activate their corresponding tyrosine kinase receptors (TKR) located on the cell surface, to induce signal 
transduction to the nucleus. TKR induces intracellular signalling cascades via the phosphorylation of the 
phosphatidylinositol 3-kinase, which in turn phosphorylates Akt and then the Akt target, mTOR (Azim, Azim et 
al. 2010). Because of the involvement of the mTOR pathway in cell progression, mTOR deregulation is associated 
with many types of human cancer (Beevers, Li et al. 2006). Mutations in the PTEN gene affect mTOR signaling 
and are commonly found in a spectrum of cancers including prostate, breast, lung, bladder, melanoma, 
endometrial, thyroid, brain, renal carcinomas and others, making it one of the most frequently mutated tumor-
suppressor genes (Beevers, Li et al. 2006). In addition, mutations in PTEN lead to Akt activation. It is known that 
active Akt regulates cell survival, cell proliferation and metabolism by controlling positively the mTOR signaling 
and negatively cell cycle inhibitors like p21 and apoptosis activators (Guertin and Sabatini 2005). However, cell 
cycle alteration is also described in different models of renal cystic disease (Lee, Battini et al. 2011). This is not 
surprising since many proteins involved in renal cystic disease show a centrosomal localization (Yoder 2007) and 
centrosome is the main coordinator of cell division (Nigg and Stearns 2011). In addition treatment with different 
drugs that inhibit cell proliferation leads to an improvement of renal function and to a slowing down of cyst 
development (Ibraghimov-Beskrovnaya 2007; Okumura, Sugiyama et al. 2009; Masyuk, Radtke et al. 2011). 
However, it is not still clear if the deregulation of the cell cycle is a consequence rather than the cause of the 
molecular mechanisms linked to cysts progression, such as the mTOR pathway activation. Further analysis will be 
necessary to elucidate this point.  
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4.3. The mTOR pathway, cilia and renal cystic disease  
The link between mTOR signaling, PKD and ciliary biology is more and more evident. Among the available 
experimental evidences the mTOR pathway has been implicated in tuberous sclerosis (TSC), a tumor suppressor 
gene syndrome associated with renal cystic disease. TSC is an autosomal dominant condition characterized by the 
formation of hamartomas in multiple tissues and organs. Renal cysts are observed in ~ 30% of patients with TSC, 
while a minority of these patients develop severe PKD. This condition is caused by mutations in the TSC1 and the 
TSC2 transcripts. The proteins encoded by the TSC1 and TSC2 genes, hamartin and tuberin, respectively, 
physically interact with each other inhibiting the mTOR pathway (Potter, Huang et al. 2001; Inoki, Li et al. 2002; 
Potter, Pedraza et al. 2003). 
Interestingly, TSC1 was shown to localize to the cilium and basal body (Yoder, Tousson et al. 2002; Nauli, 
Alenghat et al. 2003; Bonnet, Aldred et al. 2009; Hartman, Liu et al. 2009). Interestingly, the TSC2 and PKD1 
genes lie adjacent to one another on human chromosome 16p13.3, and contiguous deletions of both genes have 
been identified in patients with this early onset ADPKD (Brook-Carter, Peral et al. 1994). This observation 
suggests that TSC and PKD genes interact functionally in the pathogenesis of PKD. This is also supported by the 
observation that loss of one allele of Pkd1 worsens the renal cystic phenotype of Tsc1+/− and Tsc2+/− mice 
(Bonnet, Aldred et al. 2009; Winyard and Jenkins 2011). 
It was also described that, in different animal models, silencing of Tsc1 leads to renal cystic disease with 
upregulation of the mTOR pathway (DiBella, Park et al. 2009; Zhou, Brugarolas et al. 2009) and presence of 
longer cilia in the cells that line renal cysts (DiBella, Park et al. 2009). Moreover, mouse embryonic fibroblasts 
from Tsc1-/- and Tsc2-/- mutants show an increased number of cilia, which is not rescued by treatment with 
rapamycin, suggesting that the enhanced cilia formation is mTOR-independent (Hartman, Liu et al. 2009). 
The upregulation of the mTOR pathway was also described in different inherited forms of renal cystic disease 
(Shillingford, Murcia et al. 2006; Fischer, Jacoby et al. 2009; Becker, Opazo Saez et al. 2010; Dere, Wilson et al. 
2010). Furthermore, rapamycin, a specific inhibitor of the mTORC1 complex, causes regression of renal cysts in 
several rodent models, suggesting a role for mTOR signaling in the pathogenesis of renal cystic disease 
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(Shillingford, Murcia et al. 2006; Wu, Arcaro et al. 2009; Shillingford, Piontek et al. 2010; Zafar, Ravichandran et 
al. 2010). 
Finally recent data seem to mechanically link cilia with mTOR signaling.  Indeed, in renal tubules bending of cilia 
due to fluid flow has been shown to down-regulate mTOR signaling (Boehlke, Kotsis et al. 2010). These data 
suggest that the absence of cilia observed in a number of renal cystic diseases determines failure to sense urine 
flow and the upregulation of the mTOR pathway as a consequence.  
A number of studies indicate different possible links between mTOR, cilia and cysts and further analysis will be 
necessary to clarify and understand the connections. 
 
4.4. The mTOR pathway and autophagy 
Autophagy is a cellular degradation system in which cytoplasmic components and organelles are sequestered by 
double membrane structures called autophagosomes and then degraded by lysosomal hydrolases to supply amino 
acids and to regulate cellular homeostasis. Efficient sequestration and clearance of unneeded damaged or nonself 
components is crucial for cell survival and function and thus malfunction of autophagy contributes to a variety of 
diseases, including cancer, neurodegeneration, cardiovascular disorders and microbe infection (He and Klionsky 
2009). Autophagy is accurately regulated and the mTOR pathway is one of the main actors. This complex 
biological process is induced in response to nutrient deprivation and mTORC1, which is a downstream factor in 
insulin and/or amino acid signals, controls autophagy. Under nutrient-rich conditions, mTORC1 is incorporated 
into the ULK1 complex and subsequently phosphorylates ULK1 and Atg13, which suppress autophagic activity. 
In response to starvation, mTORC1 dissociates from the ULK1 complex, resulting in dephosphorylated ULK1 and 
Atg13 thus allowing the formation of autophagosomes (Ichimura and Komatsu 2011). In Figure 9 (modified from 
(Maiuri, Zalckvar et al. 2007)) (Rajawat and Bossis 2008), a schematic explanation for autophagy progression is 
shown, even if the molecular events are not well clarified.  The mTOR pathway controls the first steps of 
autophagy induction and membrane recruitment (steps 1 and 2). Vesicles will elongate and extremities will fuse to 
complete the double-membrane structure (step 3 and 4). Most of the proteins involved in vesicle expansion and 
maturation steps are retrieved to the original pool because they do not associate with the complete and mature 
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autophagosome. Therefore, it has been suggested that the proteins involved in autophagosome formation are 
retrieved for future use. Atg8 (LC3) is the exception; it is found on the mature autophagosome and can be used as 
a valuable marker to track these structures. The next critical step is transport and fusion of the autophagosome 
with the lysosomes (step 5). The machinery required for the process of vesicle fusion includes SNARE proteins 
and the class C Vps/HOPS complex. The last step (step 6) in the autophagic process is degradation of the 
autophagic body content by lysosomal enzymes, which ensures recycling of essential cytoplasmic contents. 
Another important actor in autophagy is the p62 protein. This protein interacts with ubiquitinated proteins and 
LC3 and seems to drive autophagic substrate selection (Riley, Kaiser et al. 2010). 
Until now, there are no evidences of the involvement of autophagy in renal cystic disease. However, several 
laboratories are looking for autophagy impairment in animal models of renal cystic diseases due to the 
experimental observation described above (paragraph 4.2. and 4.3.). 
 
MATERIALS AND METHODS 
 
Generation of Ofd1fl;creKsp mice and PCR genotyping 
Ofd1fl/+ females (Ferrante, Zullo et al. 2006) were crossed with creKsp male mice containing 1.3 kb of the Ksp-
cadherin promoter linked to the coding region of cre recombinase (Shao, Somlo et al. 2002). Animals were 
genotyped for the presence of the cre gene using the primers cre1 (GGACATGTTCAGGGATCGCCAGGCG) 
and cre2 (GCATAACCAGTGAAACAGCATTGCTG) as described in Lakso et al., PNAS, 89:6232-6 (Lakso, 
Sauer et al. 1992).  
All animal experimentation was performed under regulation of the Internal Ethical Committee and authorized by 
the Italian Ministry of Health. 
 
Generation of Ofd1fl/y;CAGGcreER-TM mice, tamoxifen injections and PCR genotyping 
Ofd1fl/+ females (Ferrante, Zullo et al. 2006) were crossed with pCAGGCre-ERTM mice, a generale deletor cre 
line that expresses Cre recombinase ubiquitously due to the presence of the β-actin promoter/enhancer CAGG 
 28 
(Hayashi and McMahon 2002). In addition, the protein is fused with the mutant form of the ligand-binding domain 
of the estrogen receptor (ERTM). This domain sequesters the Cre in the cytoplasm. Its translocation to the nucleus 
and its activity are induced after tamoxifen administration. We treated pregnant mothers with a single 
intraperitoneal injection of 100ug tamoxifen / g of weight at Embrionic stage 18.5 (E 18.5). Injections in adult 
mice were performed at P60 with a single intraperitonel injection at the dose described before. Tamoxifen was 
diluted in 10% ethanol and 90% sesam oil (SIGMA) at a final concentration of 10 mg/ml.  
Animals were genotyped using two couple of primers: cre1 (GGACATGTTCAGGGATCGCCAGGCG) and cre2 
(GCATAACCAGTGAAACAGCATTGCTG) to detect the cre gene as described in Lakso et al., PNAS, 89:6232-
6 and Fsui3 (CATTCCTGTTAGTATTTGGAGG) and RperFRT  (CGACACTGCAGAGACCTACTTC) to detect 
the floxed allele.  
 
RT-PCR and real-time PCR 
For the Ksp model, effective production of a deleted allele in the kidney was confirmed by RT–PCR (One-step 
system, Invitrogen) on kidney RNA or lung RNA, from WT and conditional mutants at P21, extracted with Trizol 
(Invitrogen), using primers Fsu1mcx and To-14020 (Ferrante, Zullo et al. 2006). Quantification of Ofd1 
inactivation was assessed by real-time PCR on cDNA (SuperScript First-Strand, Invitrogen) synthesized from 
RNA from the kidney of P20 of both Ksp and IND conditional mutants and controls. Primers used to amplify 
specifically the Ofd1 WT allele were A (TGGCAGACCACTTACAAAGATG), 
A′(AGACTGGATGAGGGGTTAATC), B (CATTCCTGTTAGTATTTGGAGG) and B′ 
(GTGTTAGGAGGGTATGAACATG). A set of primers, GapdhF (TCTTCTGGGTGGCAGTGAT) and GapdhR 
(TGCACCACCAACTGCTTAGC), that amplify the Gapdh gene were used as internal reference.  
 
Glomerular filtration rate assay 
Glomerular filtration rate (GFR) measurements were performed on adult mice at P28, P35 and P45. A 
thiobutabarbital sodium (Inactin, Sigma-Aldrich) intraperitoneal injection (120 mg/kg body weight) was given as 
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anethesthetic. The animals were surgically prepared as follows: after tracheotomy, the left carotid artery and left 
jugular vein were cannulated with polyethylene tubing. The arterial catheter was then connected to a pressure 
transducer to monitor blood pressure and to take blood samples, while the venous catheter was connected to a 
syringe pump for saline infusion. After replacing surgical fluid loss with isotonic saline, the mice were given a 
priming dose of 10µCi of [methoxy-3H] inulin, followed by a maintenance infusion in isotonic saline containing 
10µCi/h at a rate of 0.4 ml/h. The bladder was cannulated with a PE 50 tube for urine collection. After a 60 
minutes balance period, 30-minute urine samples were collected. Blood samples were taken after each clearance 
period. A total of 4 urine and blood collections were made. GFR was calculated by standard methods. 
 
Scanning electron microscopic analysis 
For SEM analysis kidneys from P7 and P14 Ksp and WT animals were fixed in Karnovsky fixative, postfixed with 
1% osmium tetroxide in 0.1 M cacodylate buffer for 1 hour at 4°C. Kidneys were sliced with a razor blade, 
dehydrated, dried with critical point-drying apparatus, and mounted on aluminium stubs coated with palladium-
gold using a cold sputter-coater. Analysis was performed with a Philips XL-20 microscope. SEM analysis on Ksp 
mutants was performed in close collaboration with Pascal Dollé (Institut de Génétique et de Biologie Moléculaire 
et Cellulaire, BP 10142, 67404 Illkirch Cedex, France).  
For SEM analysis on IND mice kidneys were fixed with 2%Glutaraldhehyde/2%Paraformaldehyde in 0.1M 
phosphate buffer. This analysis was performed in collaboration with Dr. Caroline Miller and Dr. Vincent Gattone 
(Electron Microscopy Center; Indiana University School of Medicine) following the Electron Microscopy Center 
procedures (http://anatomy.iupui.edu/core-facilities/electron-microscopy-center/emc-affiliations/emo-pkd/). 
 
Histological and Immunofluorescence assays on kidney sections 
Isolated kidneys were fixed in paraformaldeyde 4% in PBS buffer at 4°C overnight. Haematoxylin-eosin stainings 
were performed on OCT (Kaltek) sections. For immunofluorescence experiments the OCT sections were 
incubated for 30 min with 0.1% BSA, 10% goat serum in TBS before incubation with the primary antibody at 4° 
over night. Sections were then washed with TBS and incubated with secondary Abs goat anti-mouse IgG 
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conjugated to Cy3 and anti-rabbit IgG conjugated to FITC (Jackson ImmunoResearch). Stained sections were 
mounted with Vectashield (Vector Laboratories). The primary antibodies used were: anti-acetylated tubulin 
antibody (T6793, Sigma-Aldrich), anti-NaPiII cotrasporter {Custer, 1994 #8151}, anti-PCNA (sc-56, Santa Cruz 
Biotechnology), anti-Cleaved Caspase-3 (9661) and anti-phosphoS6 (Ser235/236) (2211) from Cell Signaling 
Technology (US). 
Staining for collecting ducts and distal tubules was performed with lectin from Arachis hypogaea (L7759, Sigma-
Aldrich), and with anti-Tamm-Horsfall Glycoprotein (CR2027SP, Europa Bioproducts) for detection of the thick 
ascending limb of Henle, according to manufacturer’s instructions. PAS staining (395, Sigma-Aldrich) was 
performed on kidneys from Ofd1fl;creKsp  mice at stage P23. 
Microscopy was performed with a Zeiss Axioplan 2 microscope and a Leica TCS SP2 AOBS confocal microscope 
with a 63x Neofluor Pan-Apo 1.3 nm oil objective. 
 
Rapamycin treatment and cystic index caculations 
To evaluate the response to rapamycin treatment, mice received daily intraperitoneal injections of 2.5 mg/kg 
rapamycin dissolved in vehicle (10% DMSO, 10% ethanol, and 80% saline) or vehicle alone. Rapamycin was 
administered starting at postnatal day 14 for a period of 10 days. For these experiments three sets of animals 
(mutants and controls) from three different littermates were analysed. 
Representative images of Haematoxylin-eosin -stained kidneys were acquired. A grid was placed over the images, 
and the cystic index was calculated as the percentage of grid intersection points that bisected cystic or noncystic 
areas, as previously described (Shillingford, Murcia et al. 2006). 
 
Cell lines 
Two different cell lines were used to obtain the results described in this thesis, namely HEK293 (Human 
Embryonic Kidney 293) and MDCK (Madin Darby Canine Kidney). In particular HEK293 and MDCK.  HEK293 
and MDCK cells were both cultured in high glucose Dulbecco’s modiﬁed Eagle’s Medium (DMEM) medium with 
10% Fetal Bovine Serum (FBS). 
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All the transfections performed for HEK293 cells were made using TransIT®-LT1 Transfection Reagent from 
Mirus. MDCK cells were transfected with the Amaxa Nucleofactor system according to manufaturer’s instructions 
(Cell Line Nucleofector®Kit L). 
For immunofluorescence assay a HEK293 clone stably expressing mycGFP-OFD1 was used. To obtain a stable 
clone, HEK293 cells were transfected with an empty pCDNA vector and a pCDNA vector carrying the mycGFP-
OFD1 gene, both vectors carry the resistence for the G418 antibiotic. After 48h from the transfection, the cells 
were incubated for 15 days in DMEM medium with 10% FBS and 0.5 mg/ml of G418 for selection of non-
transfected cells and few clones were picked. Clones were expanded and then analyzed by immunofluorescence 
for the expession of the GFP-OFD1 fusion protein. Western blot analysis was performed to check the levels of 
expression of the mycGFP-tagged fusion protein. Two clones were isolated that showed a convenient OFD1 
overexpression. 
 
Immunofluorecence assyas on HEK293 cells 
Cells were fixed in methanol for 6 minutes at -200 C, then washed with PBS saline solution and incubated for 1 
hour with a blocking solution (0,2% Triton X-100, 10% goat serum in PBS). The primary antibodies were diluted 
in blocking solution and cells were incubated for 2 hours at RT. Cells were then washed with PBS and incubated 
with Alexa Fluor® Dyes from Invitrogen. Before mounting with 50% glycerol in PBS nuclei were stained with 
Hoecst for 10 minutes at RT. We used the following antibodies: eIF4E (9742 Cell Signaling Technology) γ-
tubulin (clone GTU-88 T6557 SIGMA), centrin (S-19 sc-27794 Santa Cruz), eIF3δ (R-20 sc-16362 Santa Cruz). 
 
Immunoblot analysis 
Western blot studies were performed in duplicate and at least two different animals were analyzed for each group. 
Kidneys were isolated and homogenized in lysis buffer (Tris 50mM pH 7.9, 1% triton X-100, 0.1% Tween20, 
150mM NaCl, 10% glycerol, 5mM MgCl2) with protease inhibitors from SIGMA (P8340) and phosphatase 
PhosSTOP inhibitors from Roche. Western blot analysis of total proteins extracts was performed with antibodies 
for S6 (2317), P-S6 (2211), Akt (9272), P-Akt (Ser473 9271 and Thr308 9275), mTOR (2983), P-mTOR (2971), 
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p70S6Kinase (9202), P-p70S6Kinase (Thr421/Ser424 9204 and Thr389 9205) from Cell Signaling Technology 
(US), GH (sc-10364), eIF3δ (sc-16362) and eIF3η (sc-28857) from Santa Cruz Biotechnology, INC. 
Polyvinylidene difluoride (PVDF) membranes were used for Immunoblot (Millipore, US) and ECL western 
blotting reagent (Amersham, UK) or Femto (Pierce, US) for detection. 
 
RNAi in MDCK cells 
We designed two different pairs of DNA oligonucleotides (si254 and si1257) containing siRNA-expressing 
sequence targeting two regions of the canine OFD1 mRNA (XM_537958) using the software available at 
www.qiagen.com/GeneGlobe. We then cloned the annealed oligos into the expression vector pSuper 
(oligoengine). The cells were transfected with the Amaxa Nucleofactor system according to manufaturer’s 
instructions (Cell Line Nucleofector®Kit L). RNA sequences were 
GATCCCCGTGGTTTGGCCAAAGAAAATTCAAGAGATTTTCTTTGGCCAAACCAC and 
GATCCCCGGCCCAGATACGTGATTATTTCAAGAGAATAATCACGTATCTGGGCC for si254 and si1257, 
respectively. The sequence for the scrambled oligo is 
GATCCCCACTACCGTTGTTATAGGTGTTCAAGAGACACCTATAACAACGGTGTTTTTT. Cells were 
collected after 48 hours after transfection. 
 
RNAi in HEK293 cells 
HEK 293 cells were plated to a confluence of 30% the day before transfection. To silence OFD1 transcript we 
used the ON-TARGET plus smart pool against human OFD1 transcript and controls from Darmachon RNAi 
technology to a final concentration of 100uM. The transfection reagent was INTERFERIN from Polyplus. Cells 
were used for both WB analysis and immunofluorescence analysis after 72 hours from transfections. 
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Co-immunoprecipitation experiments 
Co-IP experiments were performed to demonstrate the interaction between eIF3 subunits and OFD1. We used 
HEK293 cells both non transfected or transiently transfected with a construct expressing 3XFlagOFD1, however 
all the cells were transfected with a vector overexpressing p70S6 kinase1. In addition, quantitative Co-IPs were 
performed to check the amount of endogenous P-S6 bound to endogenous eIF3η to study the formation of the PIC 
in WT HEK293 cells. Both sets of Co-IP experiments were performed with the following protocol. After 48 hours 
from plating, the cells were lysed in Buffer A (50mM Tris-HCl/1mM EDTA, 10mM MgCl2, 5mM EGTA, 0.5% 
Triton X-100 [pH 7.28]) and 250ug of total lysates were incubated for 1 hour with 5ug of specific antibodies or 
rabbit IgG as control, followed by for 1 hour of incubation with protein A-Sepharose beads. The unbound proteins 
were washed out twice with the Buffer A and once with the Buffer ST (50mM Tris-HCl, 150mM NaCl [pH 7.28]), 
while the bound fraction was analyzed by Western Blot with an antibody against the putative interactor. Buffer A 
and Buffer ST used were: Buffer A; Buffer ST The protocol used, the lysis buffer and the washing buffer are 
modified from what previous described in (Holz, Ballif et al. 2005). Proteases Inhibitors from SIGMA (P8340) 
and phosphotase inhibitors (PhosSTOP) from Roches were freshly added.  
 
Bicistronic Luciferase assay 
For luciferase reporter experiments, HEK293 cells were transfected with pRL-HCV-FL reporter plasmid 
(provided by John Blenis - Professor of Cell Biology. Department of Cell Biology Harvard Medical School 240 
Longwood Avenue Boston and previously described in Kruger et al., 2001 (Kruger, Beger et al. 2001)). Forty-
eight hours post-transfection, cells were harvested, and the luciferase activity was measured using Dual-Luciferase 
Reporter Assay System (Promega) and Glomax 96 microplate luminometer from Promega according to the 
manufacturers’ instructions. 
 
Polisome fractionation  
HEK293 CELLS: Cells were transfected with siRNA against OFD1 and with control oligos. After 48 hours cells 
were treated for 10 minutes with 100ug/ml cycloheximide (C-7698 from SIGMA) and then washed twice with 
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Hypotonic buffer (5mM Tris-HCl pH 7.5, 1.5mM KCl, 2.5mM MgCl2). Cells were lysed in 400ul of extraction 
buffer (hypotonic buffer, 0.5% triton X-100, 0.5% Na-deoxycholate, 120 U/ml RNAse inhibitors [AM2692 from 
Ambion], 3mM DTT, 100ug/ml cycloheximide) and after quantification 1mg/ml of heparin was added.  
KIDNEYS: Tissues were lysed in 1 ml of buffer 3 (50mM Tris-HCl pH 7.8, 240mM KCl, 10mM MgCl2, 250mM 
sucrose) with 5mM DTT, 100ug/ml cycloheximide, 2% triton X-100, 100 U/ml RNAse inhibitors and after 
quantification 1mg/ml of heparin was added.  
The extracts were rapidly frozen into liquid nitrogen and stored at –80°C.  
After sample preparation (which is specific for tissues or cells, see above) 1.2 mg of total lysates were layered on a 
0.5–1.5 M linear sucrose gradient (20mM Tris-HCl, pH 7.5, 80mM NaCl, 5mM MgCl2, 1mM dithiothreitol) and 
centrifuged in a SW41 rotor at 160,000 g for 2 hours at 4°C. After centrifugation, the gradient was displaced 
upward through a flow cell recording absorbance at 260 nm with the use of the density gradient fractionation 
system (Isco) and fractionated in 12 fractions as described in (Espeillac, Mitchell et al. 2011). Fractions were 
rapidly stored at –80°C. Absorbance at 260 nm was registered in a curve. The area below the curve was calculated 
using Adobe Photoshop program and the output is a read-out of general translation. 
 
RNA extraction from polysomes 
We added 1ml of isopropanol to each fraction and put the mixed fractions at –20°C over night. After 16 hours, the 
fractions were centrifuged for 30 minutes at 15000 rpm at 4°C. The pellets were resuspended in solution D (4M 
Guanidinium thiocyanate, 25mM Sodium Citrate pH 7, 0.5% Sarcosyl, 100mM 2-MeSH Mercaptoethanol) and 
180mM NaAc pH4. The RNA was extracted by phenol/chloroform protocol. After centrifugation the supernatants 
were collected and mixed. The same volume of isopropanol was added and the samples were put at –20°C over 
night. After 16 hours, the fractions were centrifuged for 30 minutes at 15000 rpm at 4°C. The pellets were washed 
with 80% of ethanol, then dryed and resuspended in water. 
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Microarray experiments 
For microarray analysis we collected polysomal and total RNA from kidneys of both IND and WT mice at P8. We 
used the Affymetrix Mouse 430A 2.0 array, 3'-IVT array, ~ 23,000 transcripts platform. The experiments were 
performed by Prof. Norman P. Gerry at the Genotyping and Microarray Center Coriell Institute for Medical 
Research (403 Haddon Ave Camden, NJ 08103). 
 
Bioinfomatic analysies 
Bioinformatic analysis was performed on the mouse Ofd1 protein sequence obtained from UCSC genome browser 
(http://genome.ucsc.edu/), we looked for known RNA binding region in the Ofd1 protein using two different 
bioinformatic tools: BindN (http://bioinfo.ggc.org/bindn/) and RNABindR 
(http://bindr.gdcb.iastate.edu/RNABindR/). For the analysis of microarray results we used the PUMA methods 
(Propagating Uncertainty in Microarray Analysis) (Rattray, Liu et al. 2006; Pearson, Liu et al. 2009).  
All the analysis were performed in collaboration with the Bioinformatic core at TIGEM. 
RESULTS 
1. Conditional models for Ofd1 
1.1. Generation and characterization of a conditional model with Ofd1 kidney-specific inactivation 
To study the role of Ofd1 protein in cysts development and to overcome the problem of embryonic male and 
perinatal female lethality observed in Ofd1 knockout (Ofd1Δ4-5 and Ofd1Δ4-5/+) mutant animals (Ferrante, Zullo et 
al. 2006), a mouse line with kidney-specific inactivation of Ofd1 was generated in professor Franco’s laboratory 
where I performed my PhD training. Females from the Ofd1-floxed line (Ofd1fl) were crossed with the Ksp-Cre 
transgenic line in which cre recombinase is under the control of the Ksp-cadherin (Cdh16) gene promoter, that is 
specifically expressed in renal tubular epithelial cells and developing genitourinary tract from E15.5 (Shao, Somlo 
et al. 2002). The resulting mice, both females (Ofd1fl/+;creKsp) and males (Ofd1fl/y;creKsp), were viable and 
indistinguishable from wild type (WT) animals at birth. RT–PCR analysis of these genotypes confirmed the 
kidney specific inactivation of Ofd1. This analysis revealed that the mutated allele is present only in the kidney of 
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mutant animals, whereas it is absent in other organs, such as the lung, where only the WT allele could be detected 
(Figure 10 A). To determine more accurately the extent of Ofd1 inactivation, we performed quantitative RT–PCR 
with primers that specifically amplify the WT Ofd1 allele on genomic DNA (primers B and B′ in Figure 10 B) 
and on RNA (primers A and A′ in Figure 10 B) obtained from kidneys of Ofd1fl;creKsp-conditional mutants (Ksp 
mutants) and controls. Primers A′ and B′ do not anneal on the deleted allele, thus allowing to specifically amplify 
the WT allele. Our analysis revealed the presence of 40 and 30% of the mutated allele on genomic DNA of whole 
kidneys from Ofd1fl/y;creKsp and Ofd1fl/+;creKsp mutants, respectively, when compared with controls. Similar results 
were obtained after analysis of the RNA (Figure 10 B). The incomplete inactivation of Ofd1 in the kidneys of 
Ofd1fl;creKsp animals was expected since cre recombinase is not expressed in all renal cells; however, one cannot 
exclude an incomplete efficiency of cre/loxP recombination. In Ofd1fl/y;creKsp males, renal cysts were not observed 
at P7, whereas dilated tubules were visible starting from P14, after this stage, cysts became larger and more 
numerous (Figure 11 B). By P35, we observed a massive replacement of the renal parenchyma by cysts. 
Histological examination revealed that cysts progression in Ofd1fl/+;creKsp female mutants was similar, although 
the number of cysts observed was reduced compared to the male mutants, probably due to the X- inactivation 
phenomenon. Cysts were confined to the medullary portion of the kidney up to P28 in Ofd1fl/y;creKsp (Figure 12 
A). Starting from P35, cysts appear in the kidney cortex (Figure 12 B), where expression of Ksp-cadherin has 
been detected at adult stages (Shao, Somlo et al. 2002). At P70, glomerular cysts were also observed, as reported 
in other conditional models obtained using the Ksp-Cre line (Gresh, Fischer et al. 2004; Hiesberger, Bai et al. 
2004) (Figure 12 C). To establish the cellular origin of cysts, we performed staining with antibodies or lectins that 
specifically label different segments of the nephron. The cysts were preferentially labelled with the antibody 
against the Tamm–Horsfall protein (THP), which labels the thick ascending limb of Henle's loop, although some 
cysts were positive for lectin Arachis hypogaea (LAH), which labels distal tubules and collecting ducts. Staining 
with an antibody to the Na-PiII (NaPiII) transporter, which marks the proximal tubules, did not label any cysts 
until P28. Taken together, these results indicated a primarily distal tubular origin of the cysts. Staining with Na-
PiII confirmed the presence of proximal cysts at P35. Staining with periodic acid-Schiff (PAS) allowed us to 
exclude the presence of fibrosis in mutant kidneys (Figure 13). The renal function of Ofd1fl;creKsp mutants was 
assessed by analysis of the glomerular filtration rate (GFR) starting from P28. At this stage, a marked reduction of 
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the GFR was observed in both male and female mutants, indicating a severe impairment of the renal function. 
GFR analysis at later stages indicated a progressive deterioration of the renal function (Figure 14) (Zullo, Iaconis 
et al. 2010). The GFR study was performed in close collaboration with Prof. Giovambattista Capasso (Division of 
Nephrology, Second University of Naples).  
 
1.2. Generation and characterization of an inducible model with Ofd1 time – specific inactivation 
In order to obtain a model in which most of the renal cells will be depleted of the Ofd1 transcript we crossed the 
Ofd1fl line with a transgenic line ubiquitously expressing a tamoxifen-inducible CreERTM protein. The Cre 
expression is regulated by the ß-actin promoter/enhancer (CAGG promoter/enhancer) that allows the ubiquitous 
expression of the gene. In addition, the protein is fused with the mutant form of the ligand-binding domain of the 
estrogen receptor (ERTM). This domain sequesters the Cre in the cytoplasm. When tamoxifen binds the ERTM 
domain the entire complex translocate to the nucleus and the Cre-mediated recombination of the DNA is allowed. 
In this system inactivation of the transcript of interest occurs more or less 24h after injection (Hayashi and 
McMahon 2002). We decided to start analyzing mice in which Ofd1 inactivation is induced at E18.5 by 
intraperitoneal injections of pregnant mothers thus resulting in inactivation of the transcript at birth in newborn 
mice. The resulting mice, both females (Ofd1fl/+;creER-TM) and males (Ofd1fl/y;creER-TM), were viable and 
indistinguishable from wild type (WT) animals at birth. All subsequent experiments on this model were performed 
in Ofd1fl/y;creER-TM male mutants which will be indicated as IND. The level of inactivation in the kidney was 
evaluated by quantitative RT-PCR and by Western Blot at different postnatal stage and is on average around 80% 
(Figure 15 A). Haematoxylin-eosin staining of kidney sections from IND mutants at different stages showed that 
tubules dilatation starts at P10 and by P18 the majority of the parenchyma was replaced by cysts (Figure 15 B and 
C). IND mutant mice die around P30. As in the Ksp mutants, the cysts were preferentially labelled with the THP 
antibody although some cysts were positive for LAH while no cysts are positive for the NapiII staining until 
postnatal stage P25 (Figure 15 D-F). The tubular origin of the cysts could not be explained by expression of the 
Cre recombinase that occurs ubiquitously. However, at P0 glomeruli are already formed while tubules are still 
growing. One possibility is that after birth tubules are more sensitive to molecular signals compared to glomeruli. 
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Moreover, glomerular cysts were visible already at P25. Overall this data indicate that the phenotype observed in 
the inducible model is more severe than that observed in the Ksp mutants. This was expected as in this model we 
obtained inactivation of the Ofd1 transcript in all renal cells thus obtaining a higher level of gene inactivation. 
Moreover, this model also allowed us to obtain a time specific inactivation of Ofd1. We wanted to evaluate 
whether Ofd1 inactivation in adult tissues could also result in the generation of renal cysts. We thus injected 
intraperitoneally tamoxifen in adult (P60) Ofd1fl/y;CAGGcreER-TM mice. These mutants in whom Ofd1 inactivation 
is obtained at P60 develop tubular cysts 9 months after Ofd1 inactivation (Figure 16). At the same stage also 
glomerular cysts could be observed (arrows in Figure 16).  
Altogether the results obtained by inactivating the Ofd1 transcript in the mouse at different time points confirms 
that Ofd1 inactivation leads to renal cystic disease and indicate that the Ofd1 transcript has a role also in the 
homeostasis of adult organs. 
 
2. Primary cilia in the Ofd1 deficient models 
To evaluate the effect of Ofd1 inactivation on cilia formation in renal cells, we performed staining with an anti-
acetylated tubulin antibody that labels the axoneme of primary cilia. At P0 and P7 in sections from Ofd1fl/y;creKsp 
mutant mice immunofluorescence analysis showed that cilia were present in all tubules of Ksp mutant kidneys, 
indicating that cilia form at precystic stages (arrowheads in Figure 17 B and C). At P14, when cysts can be 
detected, no cilia protruding from cells lining the renal cysts (Cy) were detected in both female and male mutants 
(Figure 17 H and I), whereas cilia were present in non-cystic distal tubules from the same animals (arrowheads in 
Figure 17 H and I). To confirm this observation, we performed SEM analysis on WT and mutant animals (one 
female and two male mutants). Five different slices were analyzed for each animal for a total of approximately 
100 cells observed for WT and female mutant and >200 for the male mutants. This study revealed that at P0 and 
P7, the majority of the cells examined in all animals (>95%), regardless of the genotype, showed the presence of 
cilia (arrows in Figure 17 D – F). Conversely, at P14, cilia were absent from the dilated tubules of mutant kidneys 
(Figure 17 M and N), whereas ciliated structures could be detected in WT kidney (arrow in Figure 17 L). SEM 
analysis was performed in close collaboration with Pascal Dollé (Institut de Génétique et de Biologie Moléculaire 
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et Cellulaire, BP 10142, 67404 Illkirch Cedex, France). To verify whether ciliated cells expressed the Cre 
recombinase at precystic stages, we performed immunofluorescence analysis with an anti-acetylated tubulin 
antibody and an antibody recognizing the Cre protein. Our results indicate that at precystic stages, cells expressing 
the Cre recombinase displayed primary cilia (Zullo, Iaconis et al. 2010). The same experiments were performed on 
renal sections from IND mice and compared to WT. As in the Ksp model, at P8 (precystic stage) cilia are similarly 
stained with anti-acetylated tubulin in mutants and controls (Figure 18 A and B). In addition, at P18 (cystic stage) 
we observed that only cells that underline the cysts lack the primary cilium (Cy in Figure 18 D), while in non-
dilated tubules cilia are present (arrows in Figure 18 D). Since 80% of renal cells from IND mutants don’t express 
Ofd1 (as described above in Figure 15 A), our results suggest that primary cilia do form in Ofd1-depleted cells in 
precystic stages. In addition, we performed SEM analysis on kidney sections and measured the length of the 
primary cilium. We counted 100 cilia on slices from two different IND mutants and two controls and compared 
both the mean size of cilia and the cilia length distribution (Figure 18 E and F). This analysis performed in close 
collaboration with Dr. Caroline Miller and Dr. Vincent Gattone (Electron Microscopy Center; Indiana University 
School of Medicine) revealed that the length of cilia is comparable between mutants and controls. The data 
obtained so far in both the Ksp and the IND models indicate that cilia initially formed in the absence of Ofd1 and 
were then subsequently lost after cyst formation although further analysis will be necessary to asses the ultra-
structure and the functionality of this organelle.  
 
3. Study of the mTOR pathway in OFD1 deficient models 
3.1. The mTOR pathway in murine models of OFDI 
Several lines of evidence link the mTOR pathway to cystic kidney disease (Shillingford, Murcia et al. 2006; 
Boletta 2009) and see also introduction. To test a possible alteration of this pathway in Ksp mutants, we initially 
performed immunofluorescence experiments using an antibody against the phospho-S6 ribosomal protein (P-S6), 
which is considered a read-out of the mTOR pathway. This study revealed a diffuse activation of S6 in mutant 
kidneys, which was more evident in the cells surrounding the cysts, thus suggesting an abnormal activation of the 
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mTOR pathway (Figure 19 A–G). Interestingly, deregulation of the mTOR pathway was also observed in non-
dilated tubules, suggesting that the upregulation of this pathway precedes cyst formation (arrowheads in Figure 19 
D and G). Moreover, it should also be noted that not all cysts display upregulation of the mTOR pathway 
(asterisks in Figure 19 D and F). As a control, we performed immunofluorescence analysis using both an antibody 
recognizing the Cre protein and the antibody against P-S6. Our study demonstrated that the majority of the cells 
positive for P-S6 also express the Cre recombinase in mutant animals. This result further strengthens the link 
between the upregulation of the mTOR pathway and the absence of Ofd1. We then looked at both the 
phosphorylation state and the expression levels of S6 by western blotting analysis. This study revealed an increase 
in the amount of P-S6 in Ksp mutant kidneys from both male and female mutant animals (Figure 19 H, top panel), 
whereas no changes in the total amount of S6 protein were detected (Figure 19 H, bottom panel). We also 
analyzed some components of the pathway upstream of S6. We looked at the basal level and phosphorylation 
statuses of Akt, mTOR and p70S6 kinase, but no differences were observed in kidneys from Ksp mutants 
compared to controls (Figure 20). Moreover, we also analyzed the phosphorylation status of S6 in kidneys at P8 
and at this stage the levels of P-S6 were comparable between mutants and WT. To further evaluate the role of 
mTOR signaling in cystogenesis, mutant mice and control littermates were treated with rapamycin, a specific 
inhibitor of the mTOR pathway (Sabers, Martin et al. 1995), starting from P14, when the renal cysts appear in our 
conditional knock-out model. After 10 days of treatment, animals were sacrificed at P24 and analyzed. 
Histological analysis of rapamycin-treated mutant mice showed a clear reduction in the number and size of cysts 
compared to non-treated mutant animals (Figure 21 A and B). Haematoxylin-eosin analysis revealed a normal 
structure of kidneys in control mice treated with rapamycin (Figure 21 C). We also calculated the cystic index and 
showed that it is significantly reduced in rapamycin-treated mutant mice, confirming that the rapamycin treatment 
does indeed slow cysts progression (Figure 21 D). Taken together, these results suggest that cystogenesis in our 
mouse model is mTOR-dependent (Zullo, Iaconis et al. 2010).  
As described above, the levels of Ofd1 inactivation in the Ksp model are rather low (about 30%). We were 
wondering if low differences in phosphorylation and basal levels of proteins were lost for a dilution effect. We 
thus decided to characterize the IND model in which as described before we obtained inactivation of the Ofd1 
transcript in 80% of renal cells (Figure 15 A). First, we confirmed the alteration of the mTOR pathway by 
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immunofluorescence (Figure 22 A and B) and by Western Blot (Figure 22 C) with an antibody against P-S6. In 
this model we observed that the levels of P-S6 are higher in IND mice compared to controls and we were able to 
see differences starting from P10 (central line in Figure 22 C), the stage in which cysts start to appear. Then we 
looked upstream to S6 both at the basal level and phosphorylation status of Akt, mTOR and p70S6 kinase, 
Interestingly, we found that levels of P-Akt are higher in IND mutants compared to controls (Figure 22 D). In 
particular, the alteration was observed using an antibody that recognizes Akt phosphorylated at Ser473. This site is 
a target of a positive feedback mediated by the mTORC2 complex. The phosphorylation levels of the other 
components of the pathway between Akt and S6, namely mTOR and p70S6 kinase, were comparable between 
mutants and controls as well as the phosphorylation levels of Akt at Thr308, which is a target site of upstream 
components of the mTOR pathway (Figure 23). Taken together these results suggested us that Ofd1 is likely to 
act as a downstream regulator in the mTOR pathway. In order to evaluate the involvement of the mTOR pathway 
in other affected organs we performed western blot analysis with the antibody against P-S6 on protein extracts 
from the liver of a P20 IND mutant. The levels of P-S6 in the liver of IND mice were comparable to those 
observed in WT animals (Figure 24), suggesting that the deregulation of the mTOR pathway does not occur in all 
organs and is possibly linked to renal cystogenesis. 
 
3.2. The mTOR pathway in “in vitro” OFDI deficient systems  
To further address the nature of the upregulation of this pathway, we transfected Madin–Darby canine kidney cells 
(MDCK) and human embryonic kidney cells (HEK293) with siRNAs designed against respectively the canine and 
human OFD1 transcript and measured P-S6 levels. Interestingly, the phosphorylated form of the S6 protein was 
increased in both OFD1 siRNA-treated cells as early as 48 h after transfection, when the levels of the OFD1 
transcript decrease by 60% and 80% in MDCK and HEK293 cells, respectively (Figure 25). These results suggest 
that the upregulation of mTOR is not a secondary event and is directly linked to the OFD1 inactivation.  
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4. OFD1 and the protein synthesis 
4.1. OFD1 is a component of the preinitiation complex of translation (PIC) 
To identify hypothetical partners of the OFD1 protein, HEK293 cells stably expressing the 3XflagOFD1 protein 
were generated. After plating, cells were lysed and tagged OFD1 with its interactors was isolated by affinity 
purification. The proteins isolated were digested by trypsin and the extracted peptide fragments were analyzed by 
a mass spectrometer (Figure 26). These experiments were performed in close collaboration with Professor Piero 
Pucci (CEINGE - Biotecnologie Avanzate, Naples). In the output, a number of ribosomal proteins and other 
proteins involved in the regulation of protein synthesis were listed. Because of the involvement of the mTOR 
pathway in driving protein synthesis (Ma and Blenis 2009; Van Der Kelen, Beyaert et al. 2009), I focused my 
attention on this group of hypothetical partners of OFD1. Among them, there were three different subunits of the 
eIF3 complex namely eIF3 β, ε and δ. First we confirmed the interaction between OFD1 and two different 
subunits (η and δ) of eIF3 by co-immunoprecipitation (co-IP) experiments. HEK293 cells were transiently 
transfected with a construct expressing 3XFlagOFD1 and immunoprecipitation experiments were performed using 
an antibody that specifically binds the subunit η of the eIF3 complex. The precipitate was then analyzed by 
Western blot with an antibody against the 3Xflag peptide and as shown in Figure 27 A the presence of a band 
corresponding to the OFD1 protein was detected. We then decided to confirm the interaction between endogenous 
proteins in HEK293 cells. For this experiment the immunoprecipitation was performed first with an antibody 
against eiF3η and a band corresponding to OFD1 was detected by western Blotting analysis (Figure 27 B). Then 
Co-IP experiments were performed with an antibody against OFD1 and subsequent Western Blot analysis 
performed with the specific antibodies revealed the presence of both the eiF3η and eIF3δ subunits of the eIF3 
complex (Figura 27 C). All together these results indicate that OFD1 physically interacts with the eIF3 complex.  
However, we also wondered about the subcellular compartment in which such an interaction could occur. Data 
from the literature indicate that the eIF3 complex is distributed in the cytoplasm, even if a nuclear localization for 
subunit eIF3e was described (Watkins and Norbury 2004). We thus performed immunofluorescence experiments. 
Interestingly, using an antibody against eIF3δ we observed that this subunit colocalizes with OFD1 at the 
centrosome in HEK293 cells stably overexpressing GFP-OFD1 (Figure 28). We tested by immunofluorescence in 
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HEK293 cells also an additional component of the PIC, namely eIF4E. Also in this case we could determine 
colocalization of eIF4E with different centrosomal markers, such as centrin and γ-tubulin (Figure 28). In addition 
colocalization of eIF4E with OFD1 in HEK293 overexpressing GFP-OFD1 was also demonstrated (Figure 28). 
We also quantified by confocal microscopy the levels of colocalization. Our results indicate a low percentage of 
colocalization (15%) between eIF4E and γ-tubulin, while eIF4E was shown to perfectly colocalize with GFP-
OFD1 (Figure 29). Previous data demonstrated that OFD1 localizes at the mother centriole ((Singla, Romaguera-
Ros et al. 2010) and our unpublished data). Our results suggest that also eIF4E localizes  at the mother centriole. 
Interestingly, in HEK293 treated with siRNA against OFD1, eIF4E seems to accumulate at the centrosome 
(Figure 30 panel A), suggesting that OFD1 could control the recruitment of the components of the PIC.  
 
4.2. OFD1 regulates protein synthesis in the kidney 
At this point we reasoned that OFD1 could regulate protein synthesis in the kidney and that this could represent a 
possible link with the deregulation of the mTOR pathway observed in models with Ofd1 kidney inactivation. To 
test this hypothesis we looked at the amount of P-S6 bound to the eIF3 complex in silenced HEK293 cells 
compared to WT by co-immunoprecipitation. Surprisingly, the levels of P-S6 bound to eIF3η are higher in OFD1-
siRNA treated cells compared to control cells (Figure 31). Finally, to better characterize the involvement of OFD1 
in the formation of the translation machinery we decided to extract polysomes from both HEK293 cells and 
kidneys from IND and WT mice. These experiments were performed in collaboration with my external supervisor, 
Dr. Mario Pende (Inserm U845, Université Paris Descartes). Polysomes are a cluster of ribosomes, bound to an 
mRNA molecule. Many ribosomes read one mRNA simultaneously, progressing along the mRNA to synthesize 
the same protein. Discrimination between actively translated and translationally silent mRNAs in the cell can be 
efficiently carried out using sucrose-gradient fractionation (polysome gradients), since this technique allows 
separation of free ribonucleoprotein particles (ribosome-free mRNA) from mRNAs bound to an increasing 
number of ribosomes (polysome-bound mRNA). The mTOR pathway was associated with an increase of 
polysomes due to its role in translation and polysomal fractionation is a popular method used to study general 
translation in the cells. Actively translated polysome-bound mRNAs and protein involved in the regulation of 
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translation were separated from messenger free ribonucleoproteins using sucrose gradient fractionation (Figure 32 
A). We extracted polysomes at two different stages: a precystic stage (P8) and a cystic stage (P20). Polysomal 
profile was similar between IND and WT mice at P8, while a significant difference was observed at P20 (Figure 
32 B). After polysomes fractionation we first demonstrated that polysomal fractions were not contaminate by 
cytoplasm. Indeed western blot analysis with an antibody against GAPDH revealed that this protein was absent in 
polysomal fractions from kidneys at the different stages analyzed (Figure 33 A), while, on the contrary and as 
expected, eIF3η was present (Figure 33 B lanes 2 and 3). OFD1 was also present both in polysomal kidney 
extracts and cellular extracts (Figure 33 C) and more interestingly, we showed a physical interaction between 
OFD1 and eIF3η in kidney fractions (Figure 33 B lane 4). In addition, we also observed by immunofluorescence 
that eIF4E seems to accumulate, in a precystic stage, at the centrosome in kidney sections from IND mice 
compared to WT (Figure 30 panel B). These results suggest a role for OFD1 in the regulation of the PIC at the 
stage of P8 when no differences, by looking at the polysomal profile, could be detected in the general translation. 
We decided to test whether OFD1 could have a direct role in the translation. First, in collaboration with the 
Bioinformatic core at TIGEM, we looked for known RNA binding region in the OFD1 protein using two different 
bioinformatic tools: BindN (http://bioinfo.ggc.org/bindn/) and RNABindR 
(http://bindr.gdcb.iastate.edu/RNABindR/). This analysis did not reveal significative binding region although more 
experiments will be required to address this point. We then proceeded with different approaches in the in vitro 
and in vivo available systems. We transfected HEK293 cells with a bicistronic reporter plasmid allowing both 
cap-dependent expression of renilla luciferase and expression of HCV IRES dependent firefly luciferase (cap-
independent) (Holz, Ballif et al. 2005; Csibi, Cornille et al. 2010). Firefly luciferase was used as an internal 
reporter to normalize the transfection, while renilla luciferase levels in the cells depend from cap-dependent/PIC 
driven translation efficiency. We observed that OFD1-silenced HEK293 cells had higher levels of renilla 
luciferase activity compared to control cells (Figure 34). To exclude the possibility that the accumulation of 
renilla was due to impairment of degradation we treated cells with cycloheximide, a potent inhibitor of translation 
and analysed the cells after 5 hours. After treatment the rate of degradation of the renilla was comparable between 
silenced and control cells, suggesting that normal degradation occurred and that the accumulation of renilla was 
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due to upregulation of translation (Figure 34). To confirm in vivo the impairment of translation we isolated total 
and polysomal RNA from kidneys from WT and IND mice (two for each genotype) and performed microarray 
experiments. We first compared the results obtained from polysomal and total RNA and eliminated the genes in 
common. This step allowed us to get read off the transcripts with an altered level of translation due to transcription 
impairment. This analysis indicated the presence of over 130 transcripts, which were differentially expressed 
between WT and IND mice. We then tried to cluster genes by gene ontology analysis using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) bioinformatic tool. Unfortunately no clusters could 
be identified. 
 
 4.3. Is GH involved in the deregulation of the mTOR pathway observed in Ofd1 depleted models? 
We carried out an extensive analysis of the differentially expressed gene identified by microarray analysis taking 
advantage of the available scientific literature. This effort allowed us to identify few transcripts of potential 
biological interest. Among these we focused our attention on the Growth hormone (GH). First and interestingly, 
western blot analysis on kidney lysates confirmed the higher amount of GH in IND mutants compared to WT 
animals at the precystic stage (Figure 35). 
GH has been recently demonstrated to be involved in the uptake of aminoacids (AA) and consequently in the 
activation of the mTOR pathway (Hayashi and Proud 2007). An extensive amount of published data indicates that, 
after starvation, the mTOR pathway is completely switched off and is reactivated by adding AA and/or nutrients 
(Proud 2002). It was demonstrated that stimulation of the cells only with AA mediates this response through a 
non-canonical pathway that does not involve the PI3K/Akt cascade (Gulati, Gaspers et al. 2008). Instead, upon 
addition of nutrients without AA the mTORC1 complex is activated by PI3K/Akt cascade. The reactivation of the 
mTOR pathway by nutrients and AA together occurs through the two different pathways simultaneously. 
Therefore, we decided to verify whether the mTOR pathway activation in our system is AA-dependent. To address 
this point both HEK293 OFD1-silenced and control cells were grown over-night with serum-deprived medium 
containing sodium pyruvate and AA. After 16 hours, cells were starved for 2 hours with HBSS saline solution in 
order to deprive cells of all kind of nutrients including AA. Cells were then re-stimulated for 30 minutes either 
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with AA (without nutrients) or dialyzed FBS (nutrients without AA) or complete FBS (nutrients plus AA). Treated 
cells were lysated and protein extracts were used to evaluate the levels of P-S6 by western blot analysis. 
Interestingly, our analysis showed that OFD1-silenced cells were more sensitive to AA and complete FBS re-
stimulation compared to control cells, while re-stimulation with dialyzed FBS gave similar results in silenced and 
control cells (Figure 36).  On the basis of these results we concluded that OFD1-depleted cells show an increased 
sensitivity to AA. These results were consistent with the normal phosphorylation levels described for Akt in our 
systems, indeed AA stimuli activates mTOR pathway response through a non-canonical pathway that does not 
involve the PI3K/Akt cascade. Finally we hypothesize that the increased sensitivity to AA could be due to the 
increased amount of GH observed in OFD1 depleted models. This observation pave the way to new possible 
functional approaches and may offer new links between deregulation of the mTOR pathway and renal cystic 
disease. However, additional experiments are necessary to elucidate the connections between these phenomena. 
 
5. Cell cycle and renal cysts development in OFD1 deficient murine models 
Based on the involvement of mTOR in cell proliferation we performed staining with the anti-PCNA antibody that 
recognize proliferating cells in late G1, S and early G2 phases, in WT and Ksp mutant kidneys at P21. We 
observed a marked increase of proliferating cells in mutant kidneys compared to WT (Figure 37). We confirmed 
the same results on renal sections from IND and control mice at P18. Note that, at P10 also WT sections were 
positive because the kidney is still proliferating and growing (Figure 38). We confirmed the increased cell 
proliferation with BrdU (Bromodeoxyuridine) staining that marks cells in S phase. We injected both WT and IND 
mice at P18 with BrdU and collected kidneys after 6 hours. Sections were stained with an anti-BrdU antibody and 
we observed an increased number of cells positive at the staining in sections from IND mutants compared to 
controls (Figure 39). However, PH3 (phospho-hystone 3) staining revealed a slight increase of mitotic cells in 
IND mice at P18 compared to WT, while no differences were observed at P8 and P10 (Figure 40). We also 
performed immunohistochemistry (ICH) and immunofluorescence experiments with an antibody against Ki67 that 
marks all proliferating cells and we did not observe differences between IND and WT in all stages analyzed 
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(Figure 41). These results suggest that Ofd1-depleted cells undergo a delay in cell progression and enter in a 
quiescent phase. 
 
6. Analysis of the pathways commonly involved in renal cystic disease. 
Different pathways have been involved in renal cysts development as discussed in the paragraph 3.2 of the 
Introduction. To address the possible involvement of the JACK-STAT pathway and/or Wnt pathway in the 
pathogenesis of the renal cystic phenotype observed in the IND model, we analyzed by western blot the levels of 
p21, p27 (redouts of the JACK-STAT pathway) and βcatenin (as a marker of the Wnt caconical pathway) proteins 
in lysates from kidneys of both WT and IND mice at P20. Our analysis did not reveal any differences in the total 
amount of these proteins (Figure 42). These preliminary results seem to exclude a role for both the JACK-STAT 
and the Wnt pathways.  However further experiments will be necessary to complete exclude this possibility. 
 
7. Autophagy and renal cyst in OFD1 deficient models 
As discussed above, the mTOR pathway is one of the key regulators of autophagy. To understand if this process is 
deregulated in OFD1-deficient models we looked at different markers of autophagy both in in vitro and in vivo 
systems. First we looked at LC3 by Western Blot, interestingly, we found that the levels of both LC3I and II are 
higher in OFD1-silenced-MDCK cells and kidney from the IND model at P8 compared to controls, while no 
differences were visible in the protein lysates obtained from null Ofd1∆4-5 male embryos at E10.5 and protein 
lysates from kidneys obtained from the IND animals at P20 (Figure 43). There results, although very preliminary, 
suggest that an alteration of the autophagy process may occur specifically in the renal system and in a precystic 
stage. This is an early finding and it is quite difficult at this point to predict whether there is a link between 
autophagy and cyst development and further experiments are necessary to unravel and fully understand this 
observation. 
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DISCUSSION 
My PhD project focused on the elucidation of the role of the Ofd1 transcript in the renal cystic disease observed in 
Oral-facial-digital type I syndrome. In order to do so I generated and characterized murine conditional models and 
in Ofd1-depleted cellular systems. These tools allowed me to apply in vivo and in vitro approaches and to get a 
variety of results, which will be discussed in the following sections: 
  
1. Timing of renal cystic disease in OFDI syndrome 
Ofd1 conditional inactivation at early stages of development allowed the generation of a null model in which 
female mutants die at the perinatal stage and male mutants die by the stage of E12. We demonstrated that Ofd1Δ4-
5/+ heterozygous females develop glomerular cysts as early as E14.5 (Ferrante, Zullo et al. 2006). To date, we 
never observed cysts of tubular origin in Ofd1Δ4-5 mutant females. OFDI patients display a prevalence of 
glomerulocystic kidney disease with a minor population of cysts from distal tubules (Feather, Winyard et al. 
1997). It is conceivable that glomeruli are more sensitive to Ofd1 deficiency leading to the early appearance of 
glomerular cysts in Ofd1Δ4-5 females and to the predominance of cysts of glomerular origin in OFDI patients. 
Unfortunately, due to the perinatal female lethality we cannot analyze Ofd1Δ4-5 females at more advanced stages to 
verify whether tubular cysts will develop at later stages in this model. However, in the conditional models used in 
this study cysts started to develop from the distal portion of the nephron. Concerning the Ksp mutants, the Cre is 
expressed starting from E15.5 in the medullary portion of the kidney and, accordingly, cysts originated from distal 
tubules. In these mutants, we also observed at later stages glomerular cysts and it is well established that the Ksp 
transcript is not expressed in glomerular structures (Shao, Somlo et al. 2002). The same observation has been 
reported for the KspCre;Hnf1βflox/flox mutants (Gresh, Fischer et al. 2004), while no glomerular cysts were 
observed in the Pkd1flox/-:Ksp-Cre animals (Shibazaki, Yu et al. 2008). These results suggest that the glomerular 
cysts in these models may be the product of secondary cystogenetic events, which appear to take place only when 
specific transcripts (Hnf1β and Ofd1) are inactivated. On the other hand, in the IND model, in which we 
inactivated Ofd1 ubiquitously at birth, tubular cysts do form starting from P10. One possibility could be that after 
birth tubules are more sensitive to molecular signals than glomeruli because at P0 glomeruli are already formed 
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while tubules, and consequently the entire kidney, is still growing in size until P12-P14. This growth is due to 
elongation of distal portions of the nephron and branching of tubules. However, in the IND model, we observed 
glomerular cysts at P25 when the gene is inactivated at P0 and at 11 months when the gene is inactivated at P60, 
suggesting also a direct role of Ofd1 in cysts formation in the glomeruli. In addition, it was reported that also the 
zebrafish Ofd1-deficient model has glomeruli alteration supporting a direct role of the protein in glomeruli 
development (Ferrante, Romio et al. 2009). 
These results allow us to draw two conclusions: 1) the Ofd1 transcript is important from the early stages of renal 
development and 2) Ofd1 inactivation can lead to cystic dilation of both tubular and glomerular structures.  
Different animal models for renal cystic disease have been generated, although with great variability in the stage 
and site of occurrence of renal cysts. These differences are partly due to the use of different cre lines, different 
genetic backgrounds of the murine models and to the specific role, site and timing of expression, of the genes to be 
inactivated. However, recent data showed that inactivation of Pkd1 in mice before postnatal day 12 resulted in 
severe PKD, while inactivation at postnatal day 14 and later resulted in slow-onset cystic kidney disease (Piontek, 
Menezes et al. 2007). These data identify a crucial 2-day interval (from P12 to P14) in renal maturation. As a 
consequence, inducible inactivation of Pkd1 in the mouse at different time points resulted in a very different 
disease progression (Lantinga-van Leeuwen, Leonhard et al. 2007; Piontek, Menezes et al. 2007) and this seems to 
occur also in the Ofd1 IND model. Based on these observations, we cannot exclude a specific role of the Ofd1 
transcript in renal development around P10-P14, when we observe the first dilatation of tubules in the Ksp and 
IND models. Taken together, our data suggest that Ofd1 is important in all segments of the nephron and the 
availability of different murine models will be critical to evaluate the role of Ofd1 in the formation of cysts in the 
different structures. 
 
2. The ciliary disfuntion and renal cystic disease in OFDI syndrome 
The list of ciliary proteins involved in polycystic kidney disease continues to grow, as well as the number of 
animal models in which the presence of renal cysts is associated to cilia dysfunction (Hildebrandt and Otto 2005). 
Despite this observation, there are also a few reports of animal models in which inactivation of ciliary proteins 
 50 
results in cystic kidneys and primary cilia can still be observed inside the cysts although no data is available on the 
functionality of these cilia (Phillips, Miller et al. 2004; Mokrzan, Lewis et al. 2007). Therefore, although the 
connection between primary cilium and renal cystic disease is evident, there is no clear demonstration of a direct, 
causal relationship between ciliary dysfunction and cyst formation. It is important to keep in mind that most 
cystoproteins are not exclusively localized to the cilia. For example, polycystin-1, nephrocystin and inversin, 
which are the proteins encoded by the genes responsible for ADPKD, NPHP1, and NPHP2, respectively, have also 
been detected in other cellular structures (Benzing, Gerke et al. 2001; Donaldson, Dise et al. 2002; Nurnberger, 
Bacallao et al. 2002; Boletta and Germino 2003) and are involved in cell-cell and cell-matrix interactions. We 
recently reported that OFD1 is not exclusively localized to the centrosome and basal body, but is present also in 
the nucleus (Giorgio, Alfieri et al. 2007). Impairment of the function of OFD1 in either of these subcellular 
compartments could independently result in altered tubular morphology leading to renal cysts formation. One 
challenge that remains to be addressed is to separate the cilia-specific function and properties of the various 
proteins from other functions/roles that they might have in the cell. The studies of the different murine models 
carrying inactivation of the Ift88 protein (also known as Tg737 or polaris) are particularly informative in this 
regard. Ift88 is a ciliary protein that is crucial for intraflagellar transport and cilium assembly (Taulman, Haycraft 
et al. 2001; Yoder, Tousson et al. 2002). Mice lacking Ift88 die at mid-gestation, display absence of nodal cilia, 
and exhibit neural tube and situs inversus (Murcia, Richards et al. 2000). Mice homozygous for a hypomorphic 
allele named orpk survive to birth and have cystic kidney disease associated to the presence of stunted and 
malformed cilia (Pazour, Dickert et al. 2000; Lehman, Michaud et al. 2008). Unexpectedly, transgenic 
overexpression of Ift88 in a null TgN737 background results in mice with normal nodal function and renal cystic 
disease with cilia of normal length and morphology, thus indicating a partial rescue of the functions associated to 
cilia (Brown and Murcia 2003; Watnick and Germino 2003). Altogether these results suggest that in these models 
ciliary dysfunction does not fully explain renal cystogenesis. In addition, it is also known that non-ciliary proteins 
give rise to renal cystic disease when mutated. In particular Bicaudal C is a conserved RNA-binding protein that is 
mutated in two murine models for renal cystic disease, the jcpk and bpk models (Cogswell, Price et al. 2003). 
However, recent findings link the activity of this RNA-binding protein with the orientation of cilia via Wnt 
signaling (Maisonneuve, Guilleret et al. 2009). Another example is the FLCN protein, also known as folliculin. 
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Mutations in the BHD/FLCN gene cause the Birt–Hogg–Dube' syndrome characterized by renal cystic disease and 
increased risk for renal neoplasia. The gene product localizes to the cytoplasm and the nucleus and seems to be 
involved in the regulation of the mTOR pathway (Chen, Futami et al. 2008; Hasumi, Baba et al. 2008; Hasumi, 
Baba et al. 2009).  
We have now demonstrated that, in renal epithelial cells devoid of Ofd1, primary cilia are present prior to the 
formation of renal cysts and their length is comparable to controls both in Ksp and IND mice. Cilia are then lost 
after cysts development. Interestingly the same observation was reported for a conditional mouse model with a 
Kif3A kidney specific inactivation (Lin, Hiesberger et al. 2003). To date, we do not know whether these cilia 
function normally and further experiments are needed to address this question. Our data confirm the association 
between primary cilia and renal cystic disease, and we propose that in our model the development of renal cysts 
might not be a direct consequence of the loss of cilia. Unfortunately, no data are available concerning the presence 
of cilia in precystic stages in other models for PKD and it is thus difficult to assess whether this hypothesis can be 
generally applied or it is specific to the renal cystic disease resulting from Ofd1 inactivation.  
 
3. The role of the mTOR pathway in the pathogenesis of the renal cystic disease observed in 
OFD1 deficient models 
 
3.1. Deregulation of the mTOR pathway and renal cystic disease: a common theme? 
The characterization of the in vivo model with Ofd1 inactivation we have generated allowed us to demonstrate an 
upregulation of the phospho-S6 molecule both in dilated and non-dilated tubules in the kidneys of Ksp and IND 
mutants. A possible role of the mTOR pathway in renal cystic disease is supported by reports indicating that 
rapamycin, an inhibitor of mTOR, slows down cyst progression in different animal models, suggesting that the 
mTOR pathway is a converging point in the cystogenesis (Tao, Kim et al. 2005; Shillingford, Murcia et al. 2006; 
Wahl, Serra et al. 2006; Zafar, Belibi et al. 2009). Promising and preliminary data in patients affected by ADPKD 
demonstrated that rapamycin had an effect in reducing the size of renal cysts. Patients affected by ADPKD 
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frequently receive a renal transplant without removal of the affected cystic kidneys. These patients are usually 
treated with rapamycin, used as an immunosuppressant, after renal transplantation. Interestingly, Shillingford et al 
showed a decrease of the volumes of affected kidneys in these patients thus providing evidences for possible new 
therapeutic approaches for PDKs (Shillingford, Murcia et al. 2006). 
Different clinical trials have been planned in patients affected by ADPKD to test possible treatment with 
rapamycin and its analogues (http://clinicaltrials.gov/). Studies performed on patients suggest that short-term 
administration of these drugs is safe and tolerate (Serra, Kistler et al. 2007; Serra, Kistler et al. 2009). However, 
more recent findings showed that long-term treatment of patients results in frequent drug-specific adverse events 
and did not slow the decline in progressive renal impairment (Walz, Budde et al. 2010). More studies are however 
needed to understand the possible role of molecules affecting the mTOR pathway in the amelioration of renal 
cystic disease.  
It is still not clear if the upregulation of the mTOR pathway is the cause of cyst development. Different studies, 
including our report, have shown that not all renal cysts, in ADPKD patients as well as in mouse mutants, show 
upregulation of the mTOR pathway, suggesting that this pathway could be involved in cyst expansion rather than 
cyst formation (Boletta 2009). However, the involvement of this pathway in cystogenesis is adequately reported in 
the literature and a deep and complete knowledge of the molecular mechanisms underlying deregulation of the 
mTOR pathway in renal cystic disease will be needed to understand the potential benefit of mTOR-related 
treatments. 
The mTOR pathway has also been implicated in tuberous sclerosis (TSC), a tumor suppressor gene syndrome 
associated with renal cystic disease ((Zhou, Brugarolas et al. 2009) and introduction). In addition, it was recently 
demonstrated that knockdown of one of the TSC1 zebrafish homologs leads to renal cystic disease with 
upregulation of the mTOR pathway in the cells that line renal cysts, and to the presence of longer cilia in the otic 
vesicle and pronephric ducts from morphants (DiBella, Park et al. 2009). Moreover, mouse embryonic fibroblasts 
from Tsc1-/- and Tsc2-/- mutants show an increased number of cilia, which is not rescued by treatment with 
rapamycin, suggesting that the enhanced cilia formation is mTOR-independent (Hartman, Liu et al. 2009). These 
data underline the link between the mTOR pathway, cilia and renal cysts, even if they do not clarify the role of 
cilia in the mTOR-dependent mechanisms leading to cyst pathogenesis. In our model we show, for the first time, 
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that the upregulation of mTOR pathway is evident also in non-dilated tubules where cilia appear to be normally 
present. In addition, as discussed above, there is accumulating evidence that ciliary proteins have other functions 
in the cells and that renal cysts can also be linked to non ciliary-proteins. These observations suggest that the 
activation of mTOR can occur before cyst development and that this event could determine tubules dilation. The 
persistent activation of the pathway in a portion of the cysts might contribute to the increasing in size of the cysts 
(Boletta 2009). However, in renal tubules bending of cilia due to fluid flow has been shown to down-regulate 
mTOR signaling (Boehlke, Kotsis et al. 2010). These data suggest that the absence of cilia observed in a number 
of renal cystic diseases determines failure to sense urine flow and the upregulation of the mTOR pathway as a 
consequence. Different data are published that link mTOR, cilia and cysts and further analysis are necessary to 
understand the connections. Nevertheless, the alteration of the mTOR pathway seems to be a common theme in 
renal cystic disease and this observation let us to hypothesize the existence of different mechanisms that may 
converge on the regulation of the mTOR pathway in the different models. Interestingly, we also observed that the 
levels of P-S6 are not altered in other affected organs obtained from IND mice, such as the liver. These findings 
underline the importance of this pathway in kidney development and suggest that the alteration of the mTOR 
pathway may be strictly linked to renal cysts formation. Moreover, these results support the idea that the genes 
mutated in renal cystic disease, could control the activation of this pathway preferentially in the kidney.  
Renal cystic disease is often associated with cysts in other organs, such as pancreas, ovary and liver as in the case 
of OFD type I syndrome. Until now, nothing is known about the involvement of the mTOR pathway in the 
cystogenesis of pancreas or ovary. Recent findings showed that Everolimus and other rapamycin analogs reduce 
liver size but do not ameliorate liver dysfunction, suggesting that the mTOR pathway is not directly linked to 
cystogenesis in this organ (Gevers and Drenth 2011). 
 
3.2. The role of OFD1 in the translational machinery and cell cycle control 
Our study contributed new data on the possible involvement of the OFD1 protein in the regulation of the mTOR 
pathway trough its involvement in the formation of the PIC. We hypothesize that this role is tightly linked to the 
centrosomal function of OFD1 and that the deregulation of the cell cycle and the ciliary dysfunction are direct 
consequence of the impairment of this basic function. We demonstrate that OFD1 protein colocalizes with 
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different component of the PIC at the centrosome and physically interacts with two subunits of the eIF3 complex 
both in in vitro and in vivo models. In addition in a precystic stage, OFD1 is present in polysomal fractions 
extracted from kidneys and regulates translation of specific targets. The polysomal profile is comparable between 
mutants and controls, suggesting that general translation is not affected, but microarray analysis on polysomal 
fractions indicate the presence of over one hundred mRNAs differentially expressed between WT and mutants. 
Among the possible targets we focused our attention on the GH protein. GH has an important role in the activation 
of the mTOR pathway through the uptake of AA that seems to be impaired in OFD1-silenced HEK293 cells. The 
higher level of P-S6 in our systems could be explained by the increased levels of GH associated to increased 
sensibility to AA. We proposed that OFD1 would act by controlling the formation of the PIC and the regulation of 
the translation of specific targets such as GH at the centrosome. Figure 44 illustrates our hypothesis. This 
mechanism could explain the higher levels of P-S6, the normal phosphorylation levels of protein upstream P-S6 
and the cell cycle alteration observed at P20 in the IND model. The higher amounts of GH do not allow 
downregulation of the mTOR pathway in Ofd1 deficient models compared to controls. The persistent activation of 
the pathway brings to the alteration of the general translation as showed in the IND model at P20. The 
upregulation of the mTOR pathway activates the translation of proteins involved in cell cycle regulation. In 
support to our hypothesis markers of cell cycle are altered only after cysts formation in oura and other in vivo 
models of renal cystic disease, suggesting that the alteration of the cell cycle is a consequence rather than the 
cause of cysts formation. In addition, we observed at P20 a slight increase of mitotic cells positive to PH3 and 
only few cells marked with Ki67. These latter cells should be more numerous considering the number of cells 
positive for S phase markers. These results suggest that cells probably slow down in cell progression and enter in a 
quiescent phase. However, at P20 we observed the iper phosphorylation of Akt at Ser473. It is interesting to note 
that this site is a target of mTORC2, the other complex in which mTOR is involved. This finding suggests a 
possible activation of the mTORC2 complex. The mTORC2 complex is an important regulator of the cytoskeleton 
and at this point we cannot exclude that different biological process in conjunction with the alteration of 
translation could concur to cystogenesis in our models. 
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3.3. Autophagy in OFD1 deficient models 
The mTOR pathway controls the first steps of autophagy induction and membrane recruitment and is one of the 
main inhibitors of this complex biological process. No experimental evidences have been reported to date on the 
involvement of autophagy in the development of renal cystic disease. However, because of the frequent 
deregulation of the mTOR pathway observed in models of renal cystic diseases, we looked at markers of 
autophagy in in vivo and in vitro OFD1-deficient models. The levels of both LC3I and II are higher in silenced-
MDCK cells and kidney at P8 compared to controls. There results suggest that an alteration of the autophagy 
process occurs in a precystic stage in kidneys from IND mice. Interestingly, both forms of LC3 accumulate, 
suggesting that this accumulation precede autophagosome formation. It is known that LC3I was degraded in LC3II 
by lysosomal enzimes. So when autophagy is blocked LC3II accumulates as a consequence of autophagic body 
accumulation after the fusion of autophagosome with lysosome. As described before, we observed in our models 
an impairment of the translation of specific targets. Among the targets, there is the Vps39 protein, involved in the 
fusion of autophagosome and lysosome. Interestingly this protein resulted to be downregulated in the list of 
differentially expressed polysomal RNA we obtained after the microarray experiments on polymal fractions. We 
have not confirmed yet the downregulation of this protein. It is tempting to speculate that the downregulation of 
Vps39 determines the block of the autophagic process at step 4 (figure 9) when the autophagosome is formed and 
LC3 is recruited but not digested. We cannot exclude that the activation of the mTOR pathway is a consequence of 
the activation of autophagy and that autophagy could play a role in cysts development. However, in an advanced 
cystic stage, at P20, we found that LC3I and II levels are comparable between IND and WT. Because of the 
complex regulation of the autophagy it could be that compensatory effects determine the normal level of 
autophagic markers after an initial disequilibrium possibly due to an alteration of the translation of specific 
component of the process of autophagic body formation. This is a fascinating line of research which will be 
further pursued in Prof.  Franco’ laboratory. 
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CONCLUSION  
The Oral-Facial-Digital type I syndrome (OFDI; MIM 311200) is a rare syndromic form of inherited renal cystic 
disease and belongs to the growing number of disorders ascribed to dysfunction of primary cilia. With the purpose 
of studying the role of the Ofd1 transcript in renal cystic disease, we generated two conditional Ofd1 deficient 
mouse models (Ksp and IND), which resulted in viable mice characterized by renal cystic disease and progressive 
impairment of renal function. The study of these models allowed us to demonstrate that primary cilia initially form 
and then disappear after the development of cysts, suggesting that the dysfunction of primary cilia is a 
consequence rather than the primary cause of renal cystic disease and probably have a role in renal cysts 
enlargement. Using a variety of different approaches we showed that deregulation of the mTOR pathway is 
associated to renal cystic disease in our conditional models. Interestingly, deregulation of the mTOR pathway 
seemed to specifically occur in the kidneys. This finding suggest that the mTOR pathway could have a specific 
role in renal cystogenesis and underline the importance of this pathway in kidney development. The use of both in 
vitro and in vivo systems allowed us to demonstrate that OFD1 has a role in the formation of the pre-initiation 
complex of translation (PIC) and in the regulation of translation. All together our results shed light on the 
pathogenetic mechanisms underlying OFD type I syndrome and propose new possible links between renal cystic 
disease and deregulation of the mTOR pathway. 
 
FUTURE PERSPECTIVE 
We have demonstrated that OFD1 regulates the formation of the PIC at the centrosome and that OFD1 
inactivation results in an impairment of translation. However, further analysis will be necessary to elucidate the 
molecular mechanisms underlying this event. We hypothesize that OFD1 prevents the binding of eIF4E to the PIC 
at the centrosome. We showed that eIF4E accumulates at the centrosome in the absence of OFD1, however we 
have not yet demonstrated that the binding of eIF4E to the eIF3 complex is stronger in Ofd1-depleted systems. In 
addition, we cannot exclude the possibility that OFD1 regulates the recruitment of the mRNAs at the centrosome. 
Preliminary bioinformatic analysis did not predict any RNA binding domain in the OFD1 protein sequence, 
however experimental evidences will be necessary to exclude this possibility.  
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We have also found that the translation of a number of mRNAs is impaired in IND mice at a precystic stage and so 
far we focused our attention on GH as a possible target. However, we identified more than 130 differentially 
expressed mRNAs. The next step will be to understand which molecular pathways could be deregulated by each of 
these transcripts, which translation is impaired in Ofd1-depleted systems. Bioinformatic analysis did not suggest a 
common biological function for these transcripts, so it is possible that more than one biological process is 
controlled by OFD1. Interestingly, among the putative targets there is the Vps39 protein. This protein is involved 
in the fusion of autophagosomes to lysosomes during the autophagic process. Very preliminary data suggest an 
impairment of autophagy in Ofd1-inactivated models and it will be interesting to investigate the possible 
involvement of this important biological process in the pathogenesis of renal cystic disease.  
Moreover, we hypothesize that the impairment of translation at the centrosome is the first event that leads to 
cystogenesis and that the alteration in the synthesis of different proteins cause as a consequence the deregulation 
of different pathways. To test this hypothesis we will treat mice with drugs that inhibit specifically the machinery 
of translation and we will assess whether this treatment  improves the renal cystic phenotype.  
Finally, our data indicate for the first time a role in translation for a protein important for ciliary function, namely 
OFD1. It will be important to address if this is something specific to OFD1 or if it is a novel common function of 
ciliary proteins. On the same line it will be also interesting to study possible links between the different steps 
involved in ciliogenesis and this new role of the OFD1 protein. Eventually it will also be important to link 
impairment of translation to renal cystic disease and/or the other pathological features observed in ciliopathies. 
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Table I. The clinical spectrum in OFD type I syndrome from (Macca and Franco 2009) 
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Figure 1. Clinical signs of OFDI syndrome. (A) Peculiar face of the patient and tooth abnormalities, (B) cleft 
palate, (C) lobulated tongue, (D) clinodactyly, (E and F) Brachydactyly, (G) Cystic kidney, (H) Hallux 
duplication, (I) Brachydactyly and syndactyly. (modified from  (Toprak, Uzum et al. 2006); (Macca and Franco 
2009)). 
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Figure 2. Subcellular localization of the endogenous OFD1 protein. Localization at primary cilium was 
investigated by confocal microscopy in MDCK cells. (A) Staining with the anti-acetylated-tubulin. (B) Staining 
with the anti-OFD1 antibody. OFD1 localizes at the basal body of the primary cilium as the merge in C shows. In 
Cos-7 cells studied by immunofluorescence microscopy, the anti-OFD1 detects also a diffuse signal in the 
nucleoplasm (E), which disappears when using the preimmune (G). Nuclei are stained with DAPI (D). (H) Nuclear 
and cytoplasmic fractions from whole Cos-7 cell extracts. Immunoblotting with anti-OFD1 Cter antibody shows 
that the endogenous OFD1 is present in both cellular compartments. The same amount of protein from the two 
compartments and from whole cell was loaded. To verify the purity of the extracts, the samples were 
immunoblotted with anti- βtubulin and anti-acetyl-Hystone H4 (Giorgio, Alfieri et al. 2007).  
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Figure 3. Analysis of the cortical region of the kidneys of wild-type and Ofd1Δ4/5/+ mutant animals at P0. (A 
and B) Kidney semithin sections of a P0 wild-type mouse (A) and an Ofd1Δ4/5/+ female mouse (B) stained with 
toluidine blue. In both specimens, the nephrogenic zone is normal; in the mutant, glomerular cysts are observed. 
Cy, glomerular cyst; T, tuft. Scale bars, 100 mm. (C and D) Scanning electron micrographs show normal 
glomeruli in a wild-type mouse (C) and a cystic glomerulus in the mutant mouse (D). Scale bars, 10 μm. (E and F) 
Kidney sections were immunostained with antibody against acetylated tubulin (red) marking ciliary axonemes and 
with a ZO1 antibody (green) to the tight junctions. Arrowheads indicate primary cilia in the wild-type glomerulus 
(E), and arrows indicate primary cilia in the tubuli of a wild-type (E) and a mutant (F) mouse. No cilia were 
observed on the surface of epithelial cells lining the cyst in the mutant mouse (F). Wild-type and cystic glomeruli 
are outlined with dotted line. Scale bars, 10 μm (Ferrante, Zullo et al. 2006). 
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Figure 4. Pc1 and Pc2 affect multiple signaling pathways. Summary of the effects that Pc1 and Pc2 exert on 
pathways. Multiple direct and indirect interactions allow the polycystin proteins to inhibit or stimulate pathways 
involved in cellular growth and differentiation (Chapin and Caplan 2010). 
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Figure 5. The primary cilium. (A) Motile or immotile (primary) cilia.  Structural differences determine the 
motility of a cilium. Motile cilia (right) consist of 9 doublet microtubules surrounding 2 inner singlet microtubules 
used to conduct force. Primary cilia (left) are lacking both singlet microtubules and dynein arms (from Davenport 
and Yoder, 2005). (B-D) Primary cilia in different tissues. (B) Primary cilia in the renal tubules of a mouse at P7 
stained with anti-acetylated α tubulin (red); dashed lines indicate the shape of the tubules. (C) Primary cilia in a 
bile duct of an adult murine liver (1 month old) stained with anti-acetylated α tubulin (green); nuclei were stained 
with 4′-6-diamidino-2-phenylindole (DAPI). (D) Primary cilia in the dentate gyrus of an adult murine 
hippocampus (3 months old) stained with anti-acetylated α tubulin (red); nuclei were stained with DAPI. Scale 
bars: 10 μm (D'Angelo and Franco 2011). 
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Figure 6. Phenotypic Consequences of ciliary dysfunction. In the figure all the organs and tissues commonly 
affected in ciliopathies are indicated (Goetz and Anderson 2010). 
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Figure 7. mTORC1 versus mTORC2. Distinct rapamycin sensitivities, partner proteins, substrates, and cellular 
functions distinguish the two known mTOR signaling complexes, mTORC1 (A) and mTORC2 (B) (Foster and 
Fingar 2010). 
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Figure 8. Model of Dynamic Interaction between the eIF3 Complex and mTOR/Raptor, S6K1, and eIF4B. 
Under basal conditions, S6K1 is associated with the eIF3 complex. Upon mitogen stimulation, an activation 
complex is formed in which mTOR/raptor is recruited to the eIF3 complex and phosphorylates S6K1 and 4E-BP1. 
Phosphorylation of S6K1 at T389 leads to its dissociation from the eIF3 complex (A). T389-phosphorylated S6K1 
then binds to PDK1, which phosphorylates S6K1 at T229. The fully activated S6K1 then phosphorylates eIF4B 
and S6 (B). Phosphorylation of eIF4B at S422 promotes its association with the translation preinitiation complex. 
Concurrently, mTOR/raptor phosphorylates 4E-BP1 (A), which dissociates from the cap complex, allowing 
recruitment of the eIF4G scaffold to the cap bound eIF4E as part of the eIF4F translation initiation complex (B). 
This sequence of events leads to preinitiation-complex assembly and initiation of protein translation (Holz, Ballif 
et al. 2005).  
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Figure 9. Autophagy process. The mTOR pathway controls the first steps of autophagy induction and membrane 
recruitment (steps 1 and 2). Membranes elongate to form vescicles (step 3) and extremities fuse to complete the 
double-membrane structure called autophagosome (step 4). The next critical step is transport and fusion of the 
autophagosome with the lysosomes (step 5). The last step in the autophagic process is the degradation of the 
autophagic body content by lysosomal enzymes, which ensures recycling of essential cytoplasmic contents (step 
6) (Maiuri, Zalckvar et al. 2007). 
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Figure 10. Ofd1 inactivation in Ofd1fl;creKsp (Ksp) mutant animals. (A) RT–PCR analysis showed the presence 
of the mutant Ofd1Δ4-5 allele (369 bp) only in the kidney of Ofd1fl/y;creKsp and Ofd1fl/+;creKsp mutant animals. The 
mutated allele is absent in the lung of mutants and in the kidney and lung of WT (Ofd1+/+) mice. All samples 
showed the presence of the WT allele (469 bp). No amplification was observed in the negative control. M = 
marker. (B) Quantitative RT–PCR with primers that specifically amplified the WT Ofd1 allele on genomic DNA 
(primers A and A′) and on RNA (primers B and B′). The position of the primers is displayed in the upper scheme. 
The analysis was performed on genomic DNA and RNA from kidneys of conditional mutants (Ofd1fl/y;creKsp, 
Ofd1fl/+;creKsp) and controls (Ofd1+/+). Significant differences between mutants and controls and were analyzed 
by Student’s t-test (p-value=0.05) are indicated (asterisk). Error bars represent standard error of the mean (Zullo, 
Iaconis et al. 2010). 
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Figure 11. Characterization of Ofd1fl;creKsp (Ksp) mutant animals. (A) Gross appearance of kidneys from 
Ofd1+/+ (left), Ofd1fl/+;creKsp (center) and Ofd1fl/y;creKsp (right) mice at P70. (B) Hematoxylin/eosin staining of 
kidneys sections from Ofd1fl/y;creKsp mutants at different stages. At P7, no cysts are visible. Dilated tubules 
appeared at P14 and cysts (black arrows), rapidly increased in size and number. Bar=500 mm (Zullo, Iaconis et 
al. 2010).  
Figure 12. Cysts progression in Ofd1fl;creKsp (Ksp) mutants. Hematoxylin/eosin staining of kidney sections 
from mice at P20 (A) P35 (B) and P70 (C). (A) Cysts were confined to the medulla of the kidney at P20, while no 
cysts appeared in the cortex. (B) By P35, cysts appear in the kidney cortex and we observed a massive 
replacement of the renal parenchyma by cysts. (C) Glomerular cysts (Gl) starts to develop in Ksp mutants at P70. 
Bar=50 μm. 
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Figure 13. Cysts origin in Ofd1fl/y;creKsp (Ksp) mutant animals. Kidneys from Ofd1fl/y;creKsp mutants at P21 
were stained for Tamm–Horsfall protein (THP), Arachis Hypogaea Lectin (LAH) and Na-PiII cotransporter 
(green, NaPiII). The cysts were positive for THP and LAH, thus indicating a distal tubular origin of cysts. Na-
PiII transporter, a marker of proximal tubules, did not label any cysts (Cy) at this stage. Nuclei were 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI, blue). Periodic Acid Schiff staining (PAS) on kidneys 
from Ofd1fl/y;creKsp excluded the presence of fibrosis. Bar=50 μm for THP, LAH, and NapiII panels; Bar=500 
μm for PAS staining (Zullo, Iaconis et al. 2010). 
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Figure 14. Glomerular filtration Rate (GFR) in Ofd1fl;creKsp (Ksp) mutants. GFR at different stages showed a 
reduced renal function in the kidney from mutant males (Ofd1fl/y;creKsp) and females (Ofd1fl/+;creKsp) compared 
with control littermates (Ofd1+/+) Bars = standard error of the mean. Data were analyzed by Student’s t-test.∗p-
value=0.05 (Zullo, Iaconis et al. 2010). 
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Figure 15. Characterization of the Ofd1fl/y;CAGGcreER-TM (IND) mice. (A) WB with an antibody against OFD1 
on kidney lysates from controls (WT) and Ofd1fl/y;CAGGcreER-TM  (IND) mice. (B,C) Hematoxylin/eosin staining 
of kidneys sections from IND mutants at different stages. (B) At P10, dilated tubules appear (red arrows). (C) 
Cysts, rapidly increased in size and number, replacing the majority of the parenchyma at P18. (D-F) Kidneys from 
IND mutants at P18 were stained for Na-PiII cotransporter (D green, NaPiII), Tamm–Horsfall protein (THP) and 
Arachis Hypogaea Lectin (LAH). The cysts were positive for THP and LAH, thus indicating a distal tubular origin 
of cysts. Bar=50μm for NapiII, THP and LAH panels; Bar=500 μm for Hematoxylin/eosin staining. 
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Figure 16. Renal cysts in adult Ofd1fl/y;CAGGcreER-TM (IND) mice induced at P60. Hematoxylin/eosin 
staining of WT (A) and Ofd1fl/y;CAGGcreER-TM  (IND) (B) adult renal sections at 11 months from mice injected 
with tamoxifen at P60. (A) WT mice showed a normal parenchyma (B) IND mice developed cysts both in the 
cortex and in the medullary portion of the kidney. Glomerular cysts were indicated by black arrows. Bar=200μm. 
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Figure 17. Analysis of primary cilia in renal tubules of Ofd1fl;creKsp (Ksp) mutant animals. Immunostaining 
with anti-acetylated tubulin (red) and SEM analysis revealed the presence of cilia in Ksp (Ofd1fl;creKsp ) and WT 
littermates (Ofd1+/+) at P7 in the kidney distal tubules [arrowheads in (A–C), arrows in (D–F)]. Immunostaining 
with anti-acetylated tubulin (red) showed the absence of cilia in the cells lining the cysts (Cy) and the presence of 
cilia in non-dilated tubules (arrowheads) from Ofd1fl/+;creKsp (H) and Ofd1fl/y;creKsp (I) mutants at P14. Cilia are 
normally seen in Ofd1+/+ control animals (G). SEM analysis confirm the absence of cilia from cells lining cystic 
dilations in both Ofd1fl/+;creKsp (M) and Ofd1fl/y;creKsp (N) mutants at P14, whereas cilia are  (H) and Ofd1fl/y;creKsp 
(I) mutants at P14, whereas cilia are present in control littermates at the same stage (arrows in L). Bars = 10 µm 
(A–C, G–I); 5 µm (D–F, L–N). Tubules are outlined with dotted lines (Zullo, Iaconis et al. 2010). 
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Figure 18. Analysis of primary cilia in renal tubules of Ofd1fl/y;CAGGcreER-TM (IND) mutant animals. (A-B) 
Immunostaining with anti-acetylated tubulin (red) revealed the presence of cilia in WT (A) and 
Ofd1fl/y;CAGGcreER-TM (IND) littermates (B) at P8 in the kidney distal tubules. (C) Cilia are normally stained in 
WT animals at P18. (D) Immunostaining with anti-acetylated tubulin (red) showed the absence of cilia in the cells 
lining the cysts (Cy) and the presence of cilia in non-dilated tubules (arrows) from IND mutants at P18. (E) The 
mean size of cilia and (F) the cilia length distribution are comparable between IND mutants (blue bars) and WT 
(red bars). Bar=5μm in A and B; Bar=10μm in C and D. 
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Figure 19. Upregulation of the mTOR pathway in Ofd1fl;creKsp (Ksp) mutant animals at P21. Immunostaining 
and western blot analysis with anti-phospho S6 (P-S6). The immunofluorescence revealed an higher level of P-S6 
(green) on kidney sections from Ofd1fl/+;creKsp (C and D) and Ofd1fl/y;creKsp (E–G) mutant animals when compared 
with Ofd1+/+ controls (A and B). In (B), (D) and (F), nuclei were counterstained with DAPI (blue). Fews cysts do 
not display staining with anti P-S6 (asterisks in D and F). Upregulation of P-S6 (arrowheads) is observed also in 
non-dilated tubules in both Ofd1fl/+;creKsp (D) and Ofd1fl/y;creKsp (magnification in G) mutant animals. Bars (A–G) 
= 50 µm. (H) Western blot analysis of total S6 (lower panel) and P-S6 (upper panel) on total protein extracts of 
kidneys from Ofd1+/+, Ofd1fl/+;creKsp and Ofd1fl/y;creKsp animals confirmed the upregulation of the mTOR pathway 
(Zullo, Iaconis et al. 2010). 
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Figure 20. Analysis of the proteins upstream the mTORC1 complex in Ofd1fl;creKsp (Ksp) mutants. We 
analyzed both basal and phosphorilation levels of proteins upstream mTOR in kidney lysates from mice at P21. 
No differences were observed between Ksp male mutants (1), female mutants (2) and WT (3) for Akt, mTOR and 
P70 as well as for the phosphorylated forms P-P70, P-mTOR, P-AKT. 
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Figure 21. Rapamycin treatment of Ofd1fl/y;creKsp (Ksp) animals. Rapamycin treatment significantly improves 
the renal cystic phenotype observed in Ofd1fl/y;creKsp (Ksp) animals (B) when compared to mutant animals treated 
with vehicle alone (A). Bottom panels in A and B represent higher magnification of the boxed images. In C 
kidneys from wild-type littermates treated with rapamycin or vehicle alone are shown as a control. (D) Cystic 
indices were calculated based on representative renal sections from non-treated and treated Ofd1fl/y;creKsp mice (n 
= 3 kidneys). Bars in A,B and C= 1,2 mm. Data were analyzed by Student’s t-test. ***P<0,005 (Zullo, Iaconis et 
al. 2010). 
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Figure 22. P-S6 and P-Akt analysis in Ofd1fl/y;CAGGcreER-TM (IND) mice. (A and B) Immunofluorescence 
analysis of P-S6 in WT (A) and IND (B) mice at P18 revealed an upregulation of the mTOR pathway in cells 
lining a number of cysts and non-dilated tubules. (C) Western Blot experiments on renal lysates at different stages 
showed a higher amount of P-S6 in IND mice starting from P10. (D) Levels of P-Akt (Ser473) were increased in 
IND mice compared to WT. Bar=50μm. 
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Figure 23. Analysis of the proteins upstream the mTORC1 complex in the Ofd1fl/y;CAGGcreER-TM (IND)  
mutants. We analyzed by western blot different proteins involved in the mTOR pathway in lysates from mutant 
kidneys at P8 and P18. Both total amount and phosphorylated levels of the proteins analyzed displayed no 
differences between WT (1) and IND mutants (2) in all stages analyzed. P-Akt in this figure refers to Thr308 
phosphorylation site. 
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Figure 24. Levels of P-S6 in the liver of Ofd1fl/y;CAGGcreER-TM (IND) mutants. Livers from two different IND 
mutants and WT mice were isolated. Total lysates were analyzed by Western Blot analysis to verify the levels of 
P-S6. No differences were observed between WT and IND mice. Fold change was calculated using ImageJ. 
Figure 25. Activation of P-S6 in Ofd1-depleted in vitro systems. Western blot analysis with anti phospho S6 
(PS6) antibody reveals a higher level of activated S6 protein in HEK293 (left panel) and MDCK cells (right panel) 
transfected with different siRNAs against the OFD1 transcript compared to cells transfected with the empty 
vector. Cells were collected 48 hours after transfection. 
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Figure 26. Mass spectrometry analysis to identify putatite OFD1 interactors. Schematic representation of the 
methodological approach used for mass spectrometry. Cells were transfected with a construct overexpressing the 
3XFlagOFD1 protein or with 3XFlag empty vector (EV) (step 1). Cells were lysed (step 2) and the protein with its 
interactors was immunoprecipitated with an anti-flag resin (step 3). After wash (step 4) the protein complex was 
eluted in order to obtain the resin-free protein complex (step 5).  Proteins were then loaded in an acrylamide gel 
(step 6) and the bands were cut, digested and analyzed with the mass analyzer (step 7).  
 98 
 
 
 
 
Figure 27. Co-IP experiments confirm that OFD1 interacts with components of the PIC. (A) OFD1 was 
detected with an anti Flag antibody in total lysate of HEK293 cells overexpressing 3XFlag-OFD1 (TL1), while is 
absent in total lysate of cells transfected with the empty vector (TL2). Total lysates were immunoprecipitated with 
an anti eIF3η antibody and OFD1 was detected in Co-IP performed on cells expressing 3XFlag OFD1 (1) while it 
is absent in Co-IP experiment performed on cells transfected with the empty vector (2). (B and C) Co-IP 
experiments performed on endogenous proteins confirmed the interactions between OFD1 and the two subunits of 
the eIF3 complex (eIF3δ and eIF3η). (B) Co-IP was performed with an antibody recognizing eIF3η and OFD1 
was detected by Western Blot. (C) Co-IP was performed with an antibody recognizing OFD1 and eIF3η and eIF3δ 
subunits were detected. IgG were used as control. 
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Figure 28. Centrosomal localization of the components of the PIC.  Immunofluorescence experiments showed 
that eIF3δ (red) colocalizes at the centrosome with OFD1-GFP (green) (merge third panel, first row). eIF4E 
(green) colocalizes with the γ-tubulin (red) as shown by the merge of the two signals (merge third panel, second 
row). eIF4E (red) colocalize also with centrin (green) as shown by the merge of the two signals (merge third 
panel, third row). Bar=20μm. 
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Figure 29. Analysis of the centrosomal localization of eIF4E. Immunofluorescence experiments showed that 
(A) eIF4E (green) colocalizes partially with the γtubulin (red) (dotted circles in A). (B) The colocalization was 
almost complete when cells overexpressing GFP-OFD1 (green) were stained with eIF4E (red) (dotted circles in 
B). (A-B) We quantified the percentage of colocalization with confocal microscopy. The area contained in the 
dotted circles was selected and the green and red fluorescence was calculated. In both panels the area number 3 
shows the number of pixels positive for both (red and green) florescent signals.  
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Figure 30. eIF4E accumulates at the centrosome in Ofd1 deficient models. Staining with an antibody 
recognizing the eIF4E protein (green) in HEK293 cells (A) and kidney sections from Ofd1fl/y;CAGGcreER-TM 
(IND) mice at P8 (B). Nuclei were stained with DAPI. Bar=20μm in A Bar=10μm in B. 
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Figure 31. Analysis of PIC assembly. The amount of P-S6 bound to eIF3η in control (C-) and OFD1-silenced 
HEK293 (siOfd1) cells was analyzed by Co-IP experiments. We used Rabbit Immunoglobuline G (IgG) as 
negative control for IP. Total lysate (TL) was loaded in the first lane. The fold change was calculated by using the 
Image J program. 
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Figure 32. Analysis of the polysomal profile of renal extracts from Ofd1fl/y;CAGGcreER-TM (IND) mice. (A) 
Description of Polysomes extraction (Ceppi et al. Immunome Research 2009). Cellular or tissue sample is 
homogenizated and the lysate is separated using sucrose-gradient fractionation after ultracentrifugation. This 
technique allows separation of free ribonucleoprotein particles (ribosome-free mRNA, F) from mRNAs bound to 
an increasing number of ribosomes (polysome-bound mRNA, P). (T) indicates the total remaining fractions in 
which no RNA is present. (B) The ratio between Polysomal RNA (P) and subpolisomal RNA (SP) was reported 
for both WT animals (violet) and Ofd1fl/y;CAGGcreER-TM (IND) mutants (purple). The RNA was obtained from 
Kidney (KID) of IND mutants at a precystic (P8) and at a cystic (P20) stage. The significance vas calculated with 
Bayes Factor calculation (BF) at P8 and p-value calculation at P20. 
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Figure 33. OFD1 is present in polysome fractions and coimmunoprecipitates with eIF3η. (A) We analyzed by 
immunoprecipitation the presence of the GAPDH protein in total renal lysate (first lane) and in polysomal (POL) 
fractions both at P20 (second lane) and P8 (third lane). GAPDH is exclusively detected in total lysate from kidney. 
(B) eIF3η is detected in POL fractions at both stages analyzed (second and third lanes). Co-IP between OFD1 and 
eIF3η  confirmed that the interaction occurs also in vivo (fourth lane). (C) Immunoprecipitation experiments 
performed in both HEK293 cells and renal lysates showed that OFD1 is present in polysomal fractions. 
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Figure 34. Cap-dependent translation is impaired in OFD1-silenced HEK293 cells. (A) Structure of the 
bicistronic reporter plasmid allowing cap-dependent expression of renilla luciferase and expression of firefly 
luciferase dependent on HCV IRES (Holz et al., 2005). (B) Cap-dependent translation is insulin stimulated and 
rapamycin sensitive. HEK293 cells were transfected in triplicate with the reporter plasmid. 48 hours post-
transfection, luciferase activities were measured by a dual-luciferase assay, and the renilla/firefly luciferase light-
unit ratio was calculated. The ratio was higher in OFD1-silenced cells (Hek siRNA-light yellow bar) compared 
with controls (Hek NT-violet bar). Both control and OFD1-silenced cells were treated with cycloheximide (CX) 
for 5 hours. The rate of degradation was comparable between control (HEK NT 5hCX-dark violet bar) and 
silenced (HEK siRNA 5hcx-orange bar) cells, suggesting that normal degradation occurred. Data are presented as 
the mean ± standard error. p-value<0.05. 
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Figure 35. Growth hormone (GH) levels are impaired in Ofd1fl/y;CAGGcreER-TM (IND) mutants at P8. GH 
levels were analyzed by western blot. We observed an increased amount of GH in IND mutants compared to WT. 
The fold change was calculated by using the Image J program. IND1 and IND2 are two siblings of the same 
littermate. 
Figure 36. Ofd1-depleted cells were more sensitive to AA stimulation. Control and OFD1-silenced HEK293 
cells were starved and re-stimulated with AA alone (AA), AA and nutrients  (FBS compl),  and nutrients alone 
(FBS dial). After 30 minutes of stimulation, the levels of P-S6 were observed by western blot. Ofd1-depleted cells 
were more sensitive to AA addition (second lane) compared to control (first lane). Ofd1-depleted cells (lane 4) and 
controls (lane 3) show comparable levels of P-S6 after dialyzed FBS (FBS dial, nutrients without AA) addition. 
When the stimulation was induced by complete FBS (FBS compl, nutrients plus AA) the levels of P-S6 are higher 
in Ofd1-depleted cells (lane 6) compared to control cells (lane 5). 
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Figure 37. Staining with PCNA (red) reveals an increase of proliferating renal cells from Ofd1fl/y;creKsp 
(Ksp) mutants. The number of cell positive at PCNA staining was increased in Ksp mutants (C and D) compared 
with control animals (A and B) at 21. In D cysts are outlined by dotted lines and some of the cells lining the cysts 
are positive for the staining. The same result is evident in cysts (Cy) shown in E and F where images were taken at 
higher magnification. Nuclei were stained with DAPI (blue) in B, D, and F. Bars=10 μm (A-F). 
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Figure 38. PCNA staining reveals an increased number of positive cells in Ofd1fl/y;CAGGcreER-TM (IND) 
mutants at P18. (A) PCNA staining in renal sections at P10 (panels on the left) reveals the presence of cycling 
cells both in WT and IND mice. At P18 (panels on the right) PCNA positive cells in the WT animals are reduced 
when compared to PCNA positive cells present in the IND mice both in cystic and not dilated tubules. (B) At P10 
the number of positive cells was comparable between WT and IND mice, while at P18 a significant difference was 
observed. Bayes Factor (BF) and T-Test were used to calculate the significance. BF>1.9; p-value<0.05. 
Bars=100um. 
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Figure 39. BrdU staining on renal sections reveals an increased number of cells in S-phase in 
Ofd1fl/y;CAGGcreER-TM (IND) mice at P18. (A) BrdU staining at P18 revealed an increased number of positive 
cells in IND mice  compared to WT animals. This observation was quantified in (B). T-test was used to calculate 
the p-value. p-value<0.005. Bars=50um. 
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Figure 40. PH3 staining at different stages in WT and Ofd1fl/y;CAGGcreER-TM (IND)  mice. (A) PH3 staining 
was performed at P8, P10 and P18. (B) The number of positive cells was comparable between WT and IND mice 
at P8 and P10. A slight increase of mitotic cells was observed in IND mice at P18 compared to WT. Bar=100um. 
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Figure 41. Ki67 staining in Ofd1fl/y;CAGGcreER-TM (IND) mice. (A) ICH experiments on renal sections with an 
antibody against Ki67 revealed that at the different stages analyzed (P8, P10 and P18) the number of positive cells 
was comparable between WT and IND mice. (B) We counted the cells and the significance was calculated with 
the Bayes Factor calculation. BF>2. Bars=50um. 
 112 
 
 
 
 
 
 
 
Figure 42. Analysis of LC3 levels in Ofd1-depleted models. Western blot analysis with an antibody against LC3 
I and II revealed that LC3 levels were comparable between total lysates from Ofd1+/+ control and Ofd1Δ4-5/y null 
mutants (embryos collected at E10.5) and between WT and lysates from kidneys from Ofd1fl/y;CAGGcreER-TM 
(IND) mutants at P18. Differences were detected in MDCK Ofd1-silenced cells and in IND mutants at P8 
compared to controls. 
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Figure 43. Western Blot analysis of pathways commonly involved in renal cystic disease at P20.  We 
analyzed the levels of β-catenin protein as readout of the Wnt canonical pathway, while p21 and p27 were used 
as readout of the JAK-STAT pathway. No differences were observed in total protein levels comparing whole 
lysates from WT and Ofd1fl/y;CAGGcreER-TM (IND) mutants. 
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Figure 44. Schematic representation of the possible role of OFD1 in protein synthesis. We propose that OFD1 
is part of the preinitiation complex (PIC) of translation at the centrosome where controls the formation of the PIC 
and the regulation of the translation of specific targets such as GH. In the absence of OFD1 eIF4E accumulates at 
the centrosome and the translation of specific targets is impaired.  
